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2. Summary           
Decrease in glutathione (GSH) levels was observed in cerebrospinal fluid, prefrontal 
cortex and post-mortem striatum of schizophrenia patients. Evidences suggest a defect 
in GSH synthesis at the levels of the rate-limiting synthesizing enzyme, glutamate 
cysteine ligase (GCL). Indeed, polymorphisms in the gene of the modifier subunit of 
GCL (GCLM) was shown to be associated with the disease in three different 
populations, GCLM gene expression is decreased in fibroblasts from patients and the 
increase in GCL activity induced by an oxidative stress is lower in patients’ fibroblasts 
compared to controls. GSH being a major antioxydant and redox regulator, its presence 
is of high importance for protecting cells against oxidative stress. The aim of the present 
work was to use various substances to increase GSH levels by diverse strategies. Since 
the synthesizing enzyme GCL is defective, bypassing this enzyme was the first strategy 
we used. GSH ethyl ester (GSHEE), a membrane permeable analog of GSH, succeeded 
in replenishing GSH levels in cultured neurons and astrocytes previously depleted in 
GSH by L-buthionine-(S,R)-sulfoximine (BSO), an inhibitor of GCL. GSHEE also 
abolished dopamine-induced decrease of NMDA-mediated calcium response observed 
in BSO-treated neurons. γ-Glutamylcysteine ethyl ester (GCEE), a membrane 
permeable analog of the product of GCL, increased GSH levels only in astrocytes. The 
second strategy was to boost the defective enzyme GCL. While quercetin (flavonoid) 
could increase GSH levels only in astrocytes, curcumin (polyphenol) and tert-
butylhydroquinone (quinone) were successful in both neurons and astrocytes, via an 
increase in the gene expression of the two subunits of GCL and, consequently, an 
increase in the activity of the enzyme. However, FK506, an immunosupressant, was 
unefficient. Treating astrocytes from GCLM KO mice showed that the modulatory 
subunit is necessary for the action of the substances. Finally, since cysteine is the 
limiting precursor in the synthesis of GSH, we hypothesized that we could increase 
GSH levels by providing more of this precursor. N-acetyl-cysteine (NAC), a cysteine 
donor, was administered to schizophrenia patients, using a double-blind and cross-over 
protocol. NAC significantly improved the mismatch negativity (MMN), a component of 
the auditory evoked potentials, thought to reflect selective current flowing through 
open, unblocked NMDA channels. Considering that NMDA function is reduced when 
GSH levels are low, increasing these levels with NAC could improve NMDA function 
as reflected by the improvement in the generation of the MMN.  
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3. Résumé           
Les taux de glutathion (GSH) dans le liquide céphalo-rachidien, le cortex préfrontal 
ainsi que le striatum post-mortem de patients schizophrènes, sont diminués. L’enzyme 
limitante dans la synthèse du GSH, la glutamyl-cysteine ligase (GCL), est défectueuse. 
En effet, des polymorphismes dans le gène de la sous-unité modulatrice de GCL 
(GCLM) sont associés à la maladie, l’expression du gène GCLM est diminuée dans les 
fibroblastes de patients et, lors d’un stress oxidative, l’augmentation de l’activité de 
GCL est plus faible chez les patients que chez les contrôles. Le GSH étant un important 
antioxydant et régulateur du status redox, sa présence est primordiale afin de protéger 
les cellules contre les stress oxydatifs. Au cours du présent travail, une variété de 
substances ont été utilisées dans le but d’augmenter les taux de GSH. Passer outre 
l’enzyme de synthèse GCL qui est défectueuse fut la première stratégie utilisée. L’éthyl-
ester de GSH (GSHEE), un analogue du GSH qui pénètre la membrane cellulaire, a 
augmenté les taux de GSH dans des neurones et des astrocytes déficitaires en GSH dû 
au L-buthionine-(S,R)-sulfoximine (BSO), un inhibiteur du GCL. Dans ces neurones, le 
GSHEE a aussi aboli la diminution de la réponse NMDA, induite par la dopamine. 
L’éthyl-ester de γ-glutamylcysteine (GCEE), un analogue du produit de la GCL qui 
pénètre la membrane cellulaire, a augmenté les taux de GSH seulement dans les 
astrocytes. La seconde stratégie était d’augmenter l’activité de l’enzyme GCL. Tandis 
que la quercétine (flavonoïde) n’a pu augmenter les taux de GSH que dans les 
astrocytes, la curcumin (polyphénol) et le tert-butylhydroquinone (quinone) furent 
efficaces dans les deux types de cellules, via une augmentation de l’expression des 
genes des deux sous-unités de GCL et de l’activité de l’enzyme. Le FK506 
(immunosupresseur) n’a démontré aucune efficacité. Traiter des astrocytes provenant de 
souris GCLM KO a permis d’observer que la sous-unité modulatoire est nécessaire à 
l’action des substances. Enfin, puisque la cysteine est le substrat limitant dans la 
synthèse du GSH, fournir plus de ce présurseur pourrait augmenter les taux de GSH. N-
acétyl-cystéine (NAC), un donneur de cystéine, a été administrée à des schizophrènes, 
lors d’une étude en double-aveugle et cross-over. NAC a amélioré le mismatch 
negativity (MMN), un composant des potentials évoqués auditifs, qui reflète le courant 
circulant via les canaux NMDA. Puisque la fonctionnalité des R-NMDA est diminuée 
lorsque les taux de GSH sont bas, augmenter ces taux avec NAC pourrait améliorer la 
fonction des R-NMDA, réflété par une augmentation de l’amplitude du MMN. 
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4. Introduction          
4.1 Schizophrenia 
Schizophrenia is a severe mental disorder that affects about seven people out of a 
thousand in the worldwide adult population (Mental Health Organization Website). The 
term “schizophrenia” was proposed by a Swiss psychiatrist named Eugène Bleuler. In 
1911, Bleuler used Greek roots to build the word that, according to him, illustrated the 
best the division between certain psychic functions. From an etymological point of 
view, “schizo” or skhizein means to split and “phrenia” or phrên, means mind. This 
disease is characterized by impressive symptoms, named “positives”, such as 
hallucinations, disorganized speech and behavior, delirium and paranoia. More discrete 
symptoms, the negative ones, like depression, apathy and language poverty are also 
present. At last, another important component common to patients suffering from 
schizophrenia includes cognitive symptoms, such as attention, planning, memory and 
executive functions deficits, and basic symptoms like perceptual instability. 
Schizophrenia is a heterogeneous disease and the manifestation of these symptoms is 
highly variable from a patient to another.  
Since schizophrenia was identified, medicine doctors have worked on the identification 
of symptoms, in order to better classify the disease. As for neuroscientists, they have for 
mission to understand the “how” of that complex disorder. The goal of these two 
professions is the same: finding a more efficient treatment in order to lighten the burden 
of that mentally, but also socially devastating disease. Many observations suggest the 
presence of a strong genetic component in the susceptibility to schizophrenia 
(Karayiorgou and Gogos, 1997;Lewis and Lieberman, 2000). First, family studies 
demonstrated that an individual’s lifetime risk of developing schizophrenia increases 
exponentially with degree of relation to an affected individual. Second, twin studies 
comparing the concordance for schizophrenia in monozygotic (MZ) twin pairs (who, in 
principle, share all of their genes) with the concordance in dizygotic (DZ) twin pairs 
(who share half of their genes) demonstrated that the MZ concordance rate (46%–48%) 
is significantly higher than the DZ rate (4%–14%). Finally, adoption studies comparing 
the prevalence of schizophrenia in biological relatives who have been separated by 
adoption early in life and in adoptive, not genetically related relatives who shared the 
same environment, demonstrated that the prevalence of schizophrenia is higher in the 
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biological than in the adoptive relatives. Linkage studies allowed the identification of 
various susceptible genes such as proline dehydrogenase (PRODH), neuregulin 1 
(NRG1), disrupted in schizophrenia 1 (DISC1; see Gogos and Gerber, 2006 for a more 
exhaustive list). Some other genes, such as catechol-O-methyltransferase (COMT), 
regulator of G-protein signaling 4 (RGS4) and calcineurin γ catalytic subunit were 
rather identified through candidate gene approaches (Gogos and Gerber, 2006). On the 
other hand, the significant discordance between identical twins points towards the 
importance of environmental factors. Probable environmental insults may include viral 
infections (Leweke et al., 2004), autoimmune disorders, exposure to adverse 
intrauterine events, and obstetric complications or birth traumas (Cannon et al., 
2000;Rosso et al., 2000). 
Because of the complexity of schizophrenia, the causes of this mental disorder are still 
not well understood. For more than five decades, various hypotheses trying to explain 
the causes of schizophrenia have followed or crosschecked one another. The most 
popular of the proposed hypotheses was the hyperactivity of dopamine transmission. 
This was based on the observations that antagonists of dopamine D2 receptors could 
improve positive symptoms and that dopamine-enhancing drugs show psychotogenetic 
effects (Laruelle et al., 2005). More recently, studies have shown direct evidence of 
dopamine abnormalities at the level of storage, vesicular transport, release, or reuptake 
by the presynaptic neuron (Lewis and Lieberman, 2000). Then, in the ‘90s, several 
studies have demonstrated that the administration of NMDA-R antagonists, such as 
phencyclidine (PCP) or ketamine, to control subjects lead to the apparition of symptoms 
similar to those observed in schizophrenia and exacerbates these symptoms in patients 
(Krystal et al., 1994). The ability of both noncompetitive and competitive NMDA-R 
antagonists to induce schizophrenia-like psychotic symptoms and cognitive 
impairments may indicate that endogenous dysfunction or dysregulation of NMDA-R-
mediated neurotransmission is critically implicated in the pathophysiology of 
schizophrenia (Javitt and Zukin, 1991). Also, multiple roles of the NMDA-R in 
regulating neuronal migration, neuronal differentiation, response to trophic factors, 
functional plasticity such as long-term potentiation and long-term depression, and 
finally the elaboration of synaptic spines, are consistent with the multiple functional and 
structural abnormalities documented in schizophrenia. Therefore, many therapeutic 
strategies are focusing on enhancing NMDA-R function. Indeed, treatments with 
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NMDA agonists such as glycine (Heresco-Levy et al., 1999;Javitt et al., 1994) and D-
serine (Tsai et al., 1998) provide symptoms improvement in schizophrenia. The 
dopamine and glutamatergic systems have received the most attention, although other 
systems, such as GABAergic, serotoninergic and opioid, have also been implicated. In 
addition, evidences indicate that oxidative stress is associated with schizophrenia 
patients (Mahadik et al., 1998;Reddy et al., 2003). It is however not known whether this 
oxidative stress is due to excess of reactive oxygen species (ROS) or to a deficit in 
antioxidant mechanisms or to a combination of both. An excess of ROS could originate 
from an excess of endogenous products, toxic environmental compounds, or 
pathological insults (such as infections or hypoxia/anoxia). A deficit in antioxidant 
mechanisms could be due to a genetic defect in one or some enzymes involved in the 
defense mechanisms such as superoxide dismutase, catalase or those of the glutathione 
(GSH) metabolism. Impairment of the antioxidant systems might render the organism 
particularly vulnerable during a temporary excess of ROS. Although the underlying 
mechanisms remain unclear, our laboratory proposes a genetic defect of the GSH 
system as a vulnerability factor for schizophrenia (Do et al., 2004;Do et al., 2007, in 
press). 
4.2 Glutathione deficit in schizophrenia 
Cerebrospinal fluid (CSF) of 26 patients suffering from schizophrenia and 14 control 
subjects was collected and analyzed by high-performance liquid chromatography 
(HPLC) and mass spectroscopy. These techniques allow separating the constituents of a 
mix in order to quantify them. A decrease in the concentration of GSH (-27%) and of its 
direct metabolite, g-glutamyl-glutamine (-15%) was observed in drug-naive patients 
compared to controls (Do et al., 2000). GSH levels were found to be 52% lower in 
medial prefrontal cortex using in vivo technique (Do et al., 2000) and 40% lower in 
postmortem striatum (Yao et al., 2006) of patients compare to controls. Different lines 
of evidence suggest a defect in GSH synthesis at the level of the key-synthesizing 
enzyme, glutamyl-cysteine ligase (GCL). Indeed, polymorphisms in the gene of the 
modulatory subunit of GCL (GCLM) was shown to be associated with the disease in 
three different populations and GCLM gene expression is decreased in fibroblasts of 
patients (Tosic et al., 2006). Finally, the increase in GCL activity induced by an 
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oxidative stress is lower in patients’ fibroblasts compared to controls (Gysin et al., 
2005).  
Combined with other genetic and with environmental factors such as stress, 
obstetrical complications or viral infections, a deficit in GSH could favor the 
development of schizophrenia. The role of GSH deficit proposed allows to integrate 
in a causal way many phenomenological aspects of schizophrenia. It is compatible 
with both the DA and the glutamate/NMDA hypotheses and with the 
neuropathological observations.  Life event stresses, through hypothalamic-pituitary-
adrenal axis stimulation, induce important DA release that could result, when 
combined with GSH deficit, in an increase in ROS and thus in oxidative damage to 
lipid, protein and DNA. This leads, during brain development and maturation, to 
progressive structural and functional disconnectivity. Moreover, the effect of an 
acute GSH deficit on the function of NMDA-R and on dopamine signaling indicates 
that a GSH deficit during adulthood could also contribute to the symptomatology of 
the illness (Do et al., 2007, in press).  
Various observations support the implication of a GSH deficit in the pathophysiology of 
schizophrenia. Animal models in which GSH levels are transitory decreased and 
dopamine is increased during development, present morphological and behavioral 
impairments similar to those observed in schizophrenia: decrease in dendritic spine 
density in pyramidal neurons of prefrontal cortex (Garey et al., 1998;Gheorghita et al., 
submitted;Glantz and Lewis, 2000;Kolluri et al., 2005), anomalies of parvalbumine 
immunoreactive GABA interneurons in anterior cingulate cortex (Cabungcal et al., 
2006;Lewis et al., 2005), and impairments in cognitive performance (Cabungcal et al., 
in press;Castagné et al., 2004a;Castagné et al., 2004b;Robbins, 2005). It was also shown 
that GSH, as a reducing agent, can potentiate the activity of redox sensitive proteins, 
such as NMDA-R (Choi and Lipton, 2000;Kohr et al., 1994). In addition, as the cell 
attempts to prevent damage from oxidative stress, GSH is converted to its oxidized form 
(GSSG), that is actively transported outside the cell to avoid a shift in the redox 
equilibrium. This GSSG can accumulate in the extracellular space and lead to a 
decrease in the activity of NMDA-R (Janaky et al., 1993;Sucher and Lipton, 1991). In 
vitro experiments with an animal models in which GSH levels are decreased, show 
hypofunction of NMDA-R (Steullet et al., submitted;Steullet et al., 2006). Altogether, 
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these evidences point towards the hypothesis that the dysregulation of the GSH system 
could be implicated in the reduced activity of NMDA-R. 
4.3 Glutathione 
γ-L-glutamyl-L-cysteinylglycine, or glutathione, is a tripeptide made of glutamate, 
cysteine and glycine (figure 1). This substance was first described in 1888 by de Rey-
Pailhade in a report of the Académie des Sciences (see Meister, 1989). Because of its 
affinity to sulfur, de Rey-Pailhade named this substance philothion  (from the Greek: 
philo = to love and thion = sulfur). We had to wait until 1921 for Hopkins to change the 
name of the substance to “glutathione” and to describe its reducing properties (Hopkins, 
1921).  
A   B    
Figure 1. Reduced glutathione (GSH) 
 
 
Figure 2. Oxidized glutathione (GSSG) 
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4.3.1 Redox cycle  
Glutathione can be found under its reduced (GSH; figure 1) and oxidized (GSSG; figure 
2) forms, the two of them being interchangeable following a redox cycle (figure 3). 
GSH is the substrate of an enzyme named GSH peroxidase (GPx) that reduces hydrogen 
peroxide (H2O2) to produce GSSG and H2O. GSH transhydrogenase allows GSH to act 
as an electron donor that reduces disulfide bounds found on plasmatic proteins and 
therefore lead to the formation of new thiols. Finally, GSSG is reduced by the GSSG 
reductase, a reaction requiring the oxidation of one molecule of NADPH. 
 
 
 
Figure 3. Glutathione redox cycle 
 
4.3.2 Synthesis and metabolism 
GSH is synthesized following two reactions (figure 4) catalyzed by the γ-
glutamylcysteine ligase (GCL) and the glutathion synthetase (GSS). The first reaction 
links glutamate to cysteine to produce γ-glutamylcysteine (γ-glucys), to which glycine is 
subsequently added during the second reaction. Each enzyme consumes one ATP per 
catalytic cycle. GCL is a heterodimer made of one catalytic subunit (GCLC), which 
contains the substrates binding sites, and one modulatory subunit (GCLM). The later is 
smaller and it modulates the affinity of GCLC for the substrates and inhibitors. GCL, 
the rate-limiting enzyme in the synthesis of GSH, is feedback-inhibited by GSH 
(Richman and Meister, 1975). Catabolism of GSH takes place outside the cell and is 
catalyzed by the γ-glutamyl transpeptidase (γGT) that is bound to the external surface of 
the cell membrane. Transpeptidation requires the presence of a suitable amino acid 



	
















 14
(AA; e.g. glycine or methionine) and leads to the formation of γ-glutamyl-AA and 
cysteinylglycine. The dipeptide cysteinylglycine will be hydrolyzed by dipeptidases to 
free amino acids that will be recycled to GSH synthesis. GSH can also take the path of 
the GSH-S-transferase (GST), an important detoxifying enzyme that catalyses the 
conjugation of GSH with various kinds of electrophiles. γ-glutamyl-AA is the substrate 
of the γ-glutamylcyclotransferase that converts it into 5-oxoproline. 5-oxoproline is then 
converted into glutamate by the enzyme 5-oxoprolinase, reaction requiring one ATP. 
This glutamate can then be recycled in the synthesis of new GSH.  
 
 
Figure 4. Glutathione synthesis and metabolism 
4.4 Roles of glutathione 
GSH has several roles in the nervous system (Shaw, 1998), including DNA synthesis 
and repair, and proteins and prostaglandin synthesis. But the most important of its 
properties is its faculty to protect cells against oxidative stress by regulating the redox 
state of the cell, scavenging free radical, participating in the elimination of toxins and 
acting as a source of cysteine. These roles will be discussed in more details.  
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4.4.1 Protecting cells against oxidative stress 
4.4.1.1  Oxidative stress 
Although oxygen is essential for life, highly reactive molecules, collectively termed 
reactive oxygen species (ROS), are produced during oxidative phosphorylation by 
mitochondria. ROS are therefore free radical atoms or molecules with unpaired 
electrons, including superoxide anions (O2•-), peroxides (O2•-2) and the highly reactive 
hydroxyl radical (•OH). The main source of ROS in vivo is aerobic mitochondrial 
respiration, although ROS are also produced during normal metabolism activity such as 
peroxisomal β-oxidation of fatty acids. ROS can also be produced as a consequence of 
various environmental perturbations such as extreme temperatures, ionizing radiations, 
xenobiotics, toxins, air pollutants, various biotic and abiotic stresses, and diseases 
(Scandalios, 2005). ROS are cleared from the cell by the action of the enzymes 
superoxide dismutase (SOD), leading to the production of hydrogen peroxides (H2O2; 
Johnson and Giulivi, 2005). These peroxides can be reduced by catalase in peroxisomes, 
or by glutathione peroxidase (GPx) in the cytoplasm. ROS can also be conjugated with 
antioxidants, the most important being GSH. When natural defense mechanisms of the 
organism are efficient, ROS exist in balance with biochemical antioxidants and 
detoxifying enzymes. When this balance is altered to favor ROS, oxidative stress 
occurs, resulting in a build-up of oxidatively modified molecules that can disrupt 
normal cellular activity. Thus, during times of environmental perturbations, ROS levels 
can increase dramatically, resulting in significant damage to cell structures. The main 
damage to cells results from the interaction of ROS with other molecules within the cell, 
which can cause oxidative damage to proteins, membranes and DNA (Halliwell, 
1999;Halliwell and Chirico, 1993). The effects of oxidative stress depend upon the size 
of the changes induced, with a cell being able to overcome small perturbations and 
regain its original state. However, more severe oxidative stress can cause cell death and 
even moderate oxidation can trigger the apoptosis, and more intense stresses causing 
necrosis (Lennon et al., 1991).  
Thanks to its thiol group (figure 1B, yellow moiety), GSH can scavenge free radicals, 
but it can also detoxify the potential harmful xenobiotics and their metabolites. GSH 
forms S-conjugates with electrophiles in reactions that are catalyzed by GSH-S-
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transferases (Hayes et al., 2005). Conjugation reactions usually render electrophilic 
xenobiotic intermediates less reactive and, in most cases, reduce or eliminate their 
pharmacological and/or toxic action. These conjugates must then be exported from cells 
so that they can be eliminated from the body. Very little is known about GSH and GSH-
S-conjugates transport outside the cell (Ballatori et al., 2005). A family of transporters 
named mutidrug resistance proteins (MRP) was demonstrated to mediate the cellular 
efflux of GSH conjugates and GSH itself (for a review see Cole and Deeley, 2006). 
4.4.1.2  Induction of cellular defense system  
In order to detoxify xenobiotics or ROS, phase I and II biotransformations are 
necessary. Phase I reactions may occur by oxidation, reduction or hydrolysis of 
xenobiotics to electrophilic intermediates. If the metabolites of phase I reactions are 
sufficiently polar, they may be readily excreted at this point. However, many phase I 
products are not eliminated rapidly and undergo a subsequent reaction in which an 
endogenous substrate combines with the newly incorporated functional group to form a 
highly polar conjugate. These conjugation reactions are known as phase II reactions. 
Some xenobiotics are sufficiently electrophilic to undergo conjugation without prior 
modification by phase I enzymes. GSH being a major reducing agent during phase I 
reactions and an important conjugate in phase II reactions, the utilization of GSH in 
these essential cellular defense mechanisms results in depletion of GSH pools that 
ultimately must be replenished. This is done through two major routes, reduction of 
GSSG via GSH reductase and de novo synthesis via GCL and GSS.  
It was shown that changes in the activity of GCL come along with changes in GSH 
levels, suggesting that the regulation of GCL activity is important in the maintenance of 
an appropriate amount of GSH in the cell (Morales et al., 1997). A great number of 
substances can induce the transcription of the genes coding for GCLM and/or GCLC. 
Most of these substances, if not all, are electrophiles, also named Michael reaction 
acceptors (Talalay et al., 1988). Many of these agents are inducers of phase II 
detoxifying enzymes and have been reported to initiate a protective response, 
designated as the “electrophiles counterattack” (Prestera et al., 1993). This response is 
characterized by the increase in intracellular GSH and the up-regulation of 
detoxification enzymes. The expression of these genes is regulated by the antioxidant 
response element (ARE)/electrophile response elements (EpRE) which is a cis-acting 
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regulatory element found in promoter regions of phase II genes (Rushmore et al., 1991). 
Indeed, ARE/ EpRE have been identified in the promoter regions of GST (Rushmore 
and Pickett, 1990), NAD(P)H:quinone oxidoreductase (NQO1; Favreau and Pickett, 
1991;Friling et al., 1990) and heme-oxigenase 1 (HO-1; Prestera et al., 1995), but also 
in the genes encoding the catalytic (Mulcahy et al., 1997) and the modulatory (Moinova 
and Mulcahy, 1998) subunits of GCL. 
Nrf2 is a transcription factor that binds to ARE/EpRE elements and activates genes that 
participate in the defense against free radicals and toxic insults (figure 5). Nrf2 was 
shown to be essential for the coordinate induction of phase II detoxifying and 
antioxidant enzymes, both of which are under ARE regulation (Ishii et al., 2000;Itoh et 
al., 1999). ARE activation signals, such as ROS and electrophiles, dissociate the 
cytoplasmic Nrf2-Keap1 complex, allowing Nrf2 to translocate into the nucleus 
(Jaiswal, 2004). Nrf2 heterodimerize with a partner that is still unknown, probably a 
small Maf, and this complex binds to the ARE and transcriptionally activates 
downstream target genes (Zhang and Gordon, 2004). Activation proteins (AP)-1 
transcription factors including Jun and Fos also join the complex, but their role, as well 
as that of small Mafs is still unclear. They seem to negatively or positively regulate 
ARE-mediated gene expression depending on cell types and genes, presumably to keep 
the expression of antioxidant enzymes ‘‘in check’’, to maintain the cellular defenses 
active and/or to rapidly restore induced enzymes to normal levels (Jaiswal, 2004). 
 
Figure 5. Induction of Nrf2 pathways (Zhang and Gordon, 2004) 
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4.4.2 Non-toxic storage form of cysteine 
Tissue concentrations and plasma levels of cysteine are appreciably lower than those of 
the vast majority of amino acids (Cooper, 1983). This is probably not only due to the 
fact that cysteine is readily oxidized into cystine. Because of its thiol group, cysteine is 
highly reactive. This reactivity is complex and presents a paradox. Indeed, on the one 
hand, cysteine is an antioxidant that protects cells against otherwise lethal doses of 
hydrogen peroxide; whereas, on the other, in the presence of transition metals (e.g. Fe 
and Cu, that frequently have unpaired electrons), cysteine consumes oxygen, generates 
hydrogen peroxide, and is cytotoxic (Nath and Salahudeen, 1993). GSH represents, 
therefore, a non-toxic storage form of cysteine (Cooper and Kristal, 1997). 
4.4.2.1  Astrocytes provide cysteine to neurons 
In the extracellular space, cysteine is readily oxidized to cystine. Cystine can be taken 
up by astrocytes via the system xc- (figure 4), a cystine-glutamate exchange transporter 
(Cho and Bannai, 1990). Structurally, system xc- is composed of a light-chain subunit 
(xCT), which confers substrate specificity (Sato et al., 1999), and a heavy-chain subunit 
(4F2) common to the transporter family (Mastroberardino et al., 1998). Immature 
neurons, cultivated for only 24- to 72-h take up cystine via this transport system 
(Murphy et al., 1990). This cystine uptake in neurons was shown to come along with an 
increase in GSH content in neurons cultured for 4 to 5 days, both cystine uptake and 
GSH levels decreasing thereafter (Sagara et al., 1993). Indeed, although cultured 
hippocampal neurons are capable of transporting cystine (Allen et al., 2001), neurons in 
general seem to have a preference for the transport of cysteine (Shanker et al., 2001). 
Cysteine is transported via a cysteine-glutamate sodium-dependant transporter, the 
excitatory amino acid transporter (EAAT), with a higher uptake in neurons in 
comparison to astrocytes (Shanker et al., 2001). Mice lacking EAAC1, that is widely 
expressed in neurons, show neuronal GSH deficiency (Aoyama et al., 2006). In parallel, 
it has been demonstrated that the presence of astrocytes strongly increases the content of 
GSH in neurons (Bolaños et al., 1996). It now seems evident that astrocytes are really 
important in providing cysteine to neurons (figure 6; Dringen et al., 1999;Sagara et al., 
1993). Indeed, GSH is released by astrocytes, cleaved to cysteinylglycine and the 
cysteine released by the action of dipeptidases can be transported inside neurons before 
its oxidation (figure 6A; Dringen et al., 2000). Another possibility is that cystine present 
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in the extracellular space is reduced by GSH released from astrocytes, releasing cysteine 
that can be taken up by neurons (figure6B; Wang and Cynader, 2000). Finally, 
homocysteine is a third source of cysteine. Homocysteine can be metabolized via 
transmethylation reactions, during which it is converted to methionine via the 
methionine synthase. During oxidative stress, this reaction is decreased and 
homocysteine is directed towards the transsulfuration pathway (Mosharov et al., 
2000;Vitvitsky et al., 2006), where homocysteine is metabolized to cystathionine and 
subsequently to cysteine (figure 6C). It also seems like GSH is necessary for methionine 
synthase activity (Muratore et al., 2006). 
  
Figure 6. Astrocytes provide neurons with the necessary precursors for the synthesis of 
GSH.  
4.5 Objectives of the present thesis work 
Based on impairement of GSH synthesis at the level of the limiting synthesizing 
enzyme GCL in schizophrenia, the aim of the present thesis work was to find substances 
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that could lead to an increase in GSH levels in systems with compromised GCL activity. 
Different strategies can be use to achieve this aim. The first strategy consists in using 
substances that could bypass GCL and directly increase GSH levels in astrocytes and 
neurons. The second strategy consists in the induction of GCL and the increase of its 
activity in the same cell types. Finally, a cysteine donor, the limiting precursor in the 
synthesis of GSH, was used in a clinical trial with schizophrenia patients. 
5. Strategy 1: Bypassing the limiting enzyme GCL   
5.1 Introduction 
In schizophrenia patients, the deficit in GSH observed is due to a defect at the level of 
the limiting synthesizing enzyme, GCL (Gysin et al., 2005;Tosic et al., 2006). 
Bypassing this enzyme would therefore be a considerable possibility to increase GSH 
levels. Since GSH itself is not transported inside the cell (Meister, 1989), membrane 
permeable esterified analogs of GSH and its precursor γ-glutamyl-cysteine (γ-glucys) 
were used. 
 
Figure 7. Glutathione Ethyl Ester (GSHEE) 
5.1.1 Glutathione Ethyl Ester 
Glutathione ethyl ester (GSHEE; figure 7) is the product of the esterification of a 
molecule of ethanol on the glycine carbon group of GSH. The negative charge on the 
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glycine is not present anymore, so GSHEE is membrane permeable and transported 
inside most cells. Inside the cell, GSHEE is converted by esterases into GSH, that can 
directly be used (figure 8; Anderson et al., 1985). GSH deficiency induced by inhibition 
of its synthesis by L-buthionine-(S,R)-sulfoximine (BSO), a specific inhibitor of GCL, 
may be prevented or reversed by administration of GSHEE (Meister, 1991). Indeed, 
when GSHEE is i.p.-injected (Puri and Meister, 1983) or orally administered (Anderson 
et al., 1985), GSH levels are increased  in liver and kidney of mice pretreated with BSO 
and protected these organs against acetaminophen toxicity (Puri and Meister, 1983). 
The same group showed that the ester of GSH could increase GSH levels in cultured 
human lymphoid cell line and protect these cells from the lethal effects of radiation. 
They also observed an increase in GSH levels after treatment with GSHEE in cultured 
skin fibroblasts from patients with GCL deficiency (Wellner et al., 1984). More 
recently, GSHEE was shown to successfully increase GSH levels in both BSO- and non 
BSO-treated in mixed cell cultures from rat mesencephalon (Zeevalk et al., 2007), as 
well as in primary cultured neurons from rat with small interfering RNA-mediated 
disruption of GCL activity (Diaz-Hernandez et al., 2005). 
 
Figure 8. GSHEE and GCEE enter the cell, are de-esterified, and GSH or γ-glucys can 
readily be used. 
5.1.2 γ-Glutamylcysteine Ethyl Ester 
γ-Glucys is transported into some cells, such as kidney cells, and used by GSS to form 
GSH (Anderson and Meister, 1983). Intracerebroventricular administration of γ-glucys 
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has been shown to increase rat brain GSH levels (Pileblad and Magnusson, 1992). γ-
Glucys ethyl ester (GCEE; figure 9) is the product of the esterification of a molecule of 
ethanol on the cysteine carbon group of γ-glucys. This ester was shown to be 
transported in more cells than γ-glucys itself (Anderson and Luo, 1998), showing that 
this ester moiety increases the efficacy of the substance to cross the plasma membrane. 
Treatment with this esterified GSH precursor in BSO-treated neurons could increase 
GSH levels back to control levels and could protect non-BSO treated neurons against β-
amiloid-induced oxidative stress, a model for Alzheimer’s disease (Boyd-Kimball et al., 
2005). The capacity of GCEE in increasing GSH levels after BSO treatment was also 
demonstrated in N27 cells, which are derived from embryonic rat mesencephalic 
neurons (Chinta et al., 2006). 
 
Figure 9. γ-glutamylcysteine Ethyl Ester (GCEE)  
In the present study, we evaluated the efficacy of GSHEE and GCEE in increasing GSH 
levels in cultured neurons and astrocytes from mice, when GCL was inhibited by BSO. 
In addition, we investigated whether such compounds could prevent the effect of a GSH 
deficit on NMDA responses. 
5.1.3 Effect of GSH deficit and replenishment on NMDA response 
We recently observe that neurons with a deficit in GSH induced by BSO, show an 
altered modulation of NMDA-mediated calcium response (NMDA responses) by 
dopamine (Steullet et al., submitted). In control neurons, dopamine enhanced NMDA 
responses likely via D1 receptors. In BSO-treated neurons, dopamine decreased NMDA 
responses via D2 receptors. This difference in dopamine modulation of NMDA 
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responses was mostly explained by a differential modulation of L-type calcium 
channels. The redox-sensitive ryanodine receptors (RyRs), which were enhanced in 
BSO-treated neurons, played an essential role in altering dopamine signaling in neurons 
with a GSH deficit. Data suggest that enhancement of the function of RyRs in neurons 
with low GSH levels favors D2-type receptor-mediated and calcium-dependent 
pathways, causing a change in dopamine modulation of L-type calcium channels and 
ultimately in dopamine modulation of NMDA responses. We therefore investigated 
whether increasing GSH levels with GSHEE in BSO-treated neurons would reverse the 
effects observed on the dopamine modulation of NMDA responses. 
5.2 Material and methods 
5.2.1 Primary cultures of cortical neurons 
Cultures of cortical neurons were prepared from E16-17 OF1 mice (S/IOPS OF1 from 
Charles River Laboratories, L’Arbresle, France) in accordance with the authorization 
issued by the “Office Vétérinaire du Canton de Vaud”. The pregnant female mouse was 
decapitated, then brains of embryos were removed and the cortices were isolated in 
Hanks’ balanced salt solution (137 mM NaCl, 5.3 mM KCl, 0.45 mM KH2PO4, 0.34 
mM Na2HPO4, 4.16 mM NaHCO3, 5.5 mM glucose, 1 mM sodium pyruvate, pH = 7.4) 
containing penicillin (100 u/ml) and streptomycin (100µg/ml). Cortical cells were 
mechanically dissociated with a Pasteur pipette, centrifuged and resuspended in 
Neurobasal medium (Invitrogen) supplemented with 2% B27 (Invitrogen), 500 µM 
glutamine and 30µM glutamate. Neurons were plated on poly-L-ornithine-coated 
culture dishes at a density of 800 cells/mm2 or on poly-L-ornithine-coated glass 
coverslips at a density of 600 cells/mm2. Cells were maintained at 37°C and in a 
humidified 5% CO2 atmosphere. 
5.2.2 Primary cultures of cortical astrocytes 
Cortices from P1-3 OF1 mice (S/IOPS OF1 from Charles River Laboratories, 
L’Arbresle, France) were dissected in DMEM medium (Invitrogen, Carlsbad, CA, 
USA) supplement with 10% fetal bovine serum (Invitrogen) and containing penicillin 
(100 u/ml) and streptomycin (100µg/ml). Cortical cells were mechanically dissociated 
through needles with decreasing diameters, centrifuged at 500 rpm for 5 min and 
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resuspended in the same supplemented DMEM medium. Astrocytes were harvested on 
poly-L-ornithine-coated dishes and left to grow at 37°C in a humidified 5% CO2 
atmosphere.  
5.2.3 Treatments 
Four to six days-old neurons and 14-15 days-old astrocytes were treated as shown on 
figure 10. GSH deficit was induced with L-buthionine-(S,R)-sulfoximine (BSO), a 
specific inhibitor of GCL. A dose-response curve showing the effect of BSO on GSH 
levels was established for the two cell types. Both 100µM-treatment BSO in neurons 
and 10µM-treatment BSO in astrocytes led to a decrease in GSH levels of about 70%. 
Cells were incubated for 24 hours in Neurobasal medium containing 100µM BSO for 
neurons and 10µM BSO for astrocytes, supplemented with 500µM glutamine and 2% 
special B27 without antioxidants (Invitrogen, Carlsbad, CA, USA). Controls were 
incubated in the same medium, but without BSO. Seven hour after the beginning of 
BSO incubation, either GSHEE or GCEE was added, or not, to the medium for 24h. 
GSH levels and LDH activity were then assessed. 
 Figure 10. Experimental design 
5.2.4 Total GSH measurements 
Quantification of total GSH content in cells was performed with an assay based on the 
Tietze method (Tietze, 1969). Cells were washed twice with ice-cold PBS (150mM 
NaCl, 3mM KCl, 1.5mM KH2PO4 and 7.9mM Na2HPO4), and scrapped out of the dish 
with 100 µl ice-cold PBS containing 1-2.5mM EDTA. After sonication, an aliquot was 
reserved for subsequent analysis of protein content using the Advanced Protein Assay 
(Cytoskeleton, Denver, CO, USA). Proteins in the remaining cell solution were 
precipitated with 5-Sulfosalicylic acid (SSA) and precipitate was removed from solution 
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by centrifugation. Triethanolamine (TEA) was added to the supernatant to bring pH >7. 
In a well of a 96-well plate, 100 µl of supernatant diluted in PBS as much as needed, 
was mixed with 100 µl of freshly made reaction solution [PBS with 2.5mM EDTA, 
0.3mM DTNB, 0.3mM NADPH and 1 U/ml GSH reductase]. The absorbance at 405 nm 
was measured with a plate reader 20 sec after mixing and then at 15 sec intervals for 1 
min. The rate of increase in absorbance, which measures the cyclic reduction of DTNB 
by GSH, was proportional to the total GSH. Measurements were done in duplicates. 
Concentration of GSH in sample solution was determined by comparison with a series 
of freshly-made GSH standard solutions. GSH content in cells are expressed in nmole 
GSH/mg proteins. The possible presence of GSHEE in samples from GSHEE-treated 
neurons did not interfere with the measurements of GSH as verified using standard 
solutions of GSHEE alone or with GSH. 
5.2.5 Assessment of cell viability 
Cell viability was assessed by measuring the activity of lactate dehydrogenase (LDH) in 
the culture medium (adapted from Dringen et al., 1998). When cells are dying, cell 
membranes become permeable and cells release their content, including LDH, in the 
medium. An aliquot of culture medium was collected and kept at – 80°C. For 
measurement of LDH activity, 50 µl of the collected medium was mixed with 100 µl of 
0.1M potassium phosphate buffer (pH 7.4) and 150 µl of a freshly-made reaction 
solution [6.4mM sodium pyruvate and 0.8mM NADH in 0.1 M potassium phosphate 
buffer]. The decrease in absorbance at 340 nm, recorded every minute for 10 min using 
a plate reader, was proportional to LDH activity. Measurements were done in 
duplicates. LDH activity in the medium was scaled with the activity of a series of LDH 
standard solutions. The amount of LDH in the medium was then reported to the amount 
of proteins measured in the cells of the corresponding dish. 
5.2.6 Calcium experiments 
Changes in intracellular calcium concentrations were measured at room temperature 
with the calcium indicator dye, Fluo-4AM (Molecular probes, Invitrogen, Carlsbad, CA, 
USA; Thomas et al., 2000). Fluo-4 was dissolved to 5mM in DMSO/20% pluronic F-
127 (Molecular probes, Invitrogen, Carlsbad, CA, USA), and stored at –20°C until use. 
A poly-L-ornithine-coated coverslip with attached control or treated neurons was 
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washed twice with HEPES buffer (140mM NaCl, 5mM KCl, 20mM glucose, 2mM 
CaCl2, 10mM HEPES, pH=7.35), incubated in the dark for 30 min in HEPES buffer 
containing 5 µM Fluo-4AM, and kept for 30 min in HEPES buffer to allow de-
esterification of the dye. The coverslip was then washed with HEPES buffer, mounted 
on a recording chamber, and placed on an epifluorescence microscope (Nikon Eclipse 
TE300, Nikon Inc., Japan). HEPES buffer flowed continuously at ~1 ml/min through 
the recording chamber. Images were collected every 2 s with a CCD camera (Princeton 
Instruments, Trenton, NJ, USA) coupled to an acquisition system (Metamorph, 
Universal Imaging Corporation, West Chester, PA, USA). The excitation light was 
provided by a 100 W Xenon lamp. The excitation and emission filters were 465-495 nm 
and 515-555 nm, respectively. A fast step perfusion system (Warner Instruments 
Corporation, Hamden, CT, USA) was used to present stimuli over the neurons of 
interest. Images were analyzed off-line with the software Metamorph (Universal 
Imaging Corporation, West Chester, PA, USA). The fluorescence of each neuron was 
corrected by subtraction of the background fluorescence that was determined in areas 
with no cells. Calcium-sensitive fluorimetric changes upon stimulation were normalized 
with the baseline fluorescence (F0) measured before stimulation, and were expressed as 
100*(delta F)/F0, where delta F was the fluorescence change induced by a stimulation. 
Responses were quantified at their peak and were compared across treatments using sets 
of neurons from sister culture dishes of a same cultures. NMDA-mediated calcium 
responses were typically induced by a mixture of 5µM NMDA and 5µM D-serine. 
Dopamine modulation of calcium responses was investigated by superfusing freshly-
made dopamine for 1 min before and during the NMDA stimulation. 
5.2.7 Statistical analysis 
The effect of treatments (presence or absence of BSO and GSHEE) on GSH content or 
cell viability (dependent variables) was analyzed by one-way ANOVA followed by 
planned pair-wise comparisons between treated groups. Statistical significance was 
corrected for multiple comparisons using the sequential Bonferroni test with the Dunn-
Šidák method (Sokal and Rohlf, 1997). Significant probability level was set to p  0.05 
Because NMDA-mediated calcium responses usually did not follow normal 
distributions according to the Shapiro-Wilk test, non-parametric statistic was used. First, 
the effects of BSO and GSHEE treatment (presence or absence of treatment) and 
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dopamine (absence vs. presence) on calcium responses (dependent variable) were 
analysed using a two-way ANOVA for ranked data [Scheirer-Ray-Hare extension of the 
Kruskall-Wallis test (Sokal and Rohlf, 1997)]. Planned pair-wise comparisons of 
calcium responses between groups were then performed with Kruskall-Wallis test and 
statistical significance was corrected for multiple comparisons as previously described. 
Significant probability level was set to p  0.05. 
5.3 Results 
5.3.1 Effect of GSHEE on cultured astrocytes and neurons 
In both neurons and astrocytes, GSH deficit was induced by 24-h treatment with L-
buthionine-(S,R)-sulfoximine (BSO), an inhibitor of GCL. In neurons (figure 11A), a 
significant 70% decrease in GSH levels (p < 0.001) was observed after a treatment with 
100µM BSO. A 24-h treatment with 1mM GSHEE significantly increased GSH levels 
in both control (p < 0.001) and BSO-treated neurons (p < 0.001). In BSO-treated 
neurons, GSHEE increased GSH levels to levels similar to those measured in control 
neurons. Cell viability was affected neither by BSO nor by GSHEE treatment, as 
assessed by measuring the activity of LDH from culture media (figure 11B). 
In astrocytes, a significant 73% decrease in GSH levels (p < 0.001) was observed after a 
treatment with 10µM BSO (figure 12A). Compared to neurons, astrocytes appear to be 
more sensitive to BSO. Indeed, the same percentage of decrease in GSH levels was 
obtained with 10 times less BSO in astrocytes compared to neurons. Higher 
concentrations of GSHEE are necessary to increase GSH levels in astrocytes compared 
to neurons. In BSO-treated astrocytes, 3mM GSHEE fully replenished GSH contents to 
levels similar to those observed in control astrocytes (p < 0.001). 1mM or 2mM GSHEE 
only partially increased GSH levels in a dose-dependant manner. By contrast with 
neurons, 1mM, 2mM or 3mM GSHEE, did not lead to any significant increase in GSH 
levels in non-BSO treated astrocytes. Cell viability was affected neither by BSO nor by 
GSHEE treatment, as assessed by measuring the activity of LDH from culture media 
(figure 12B). 
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A  GSH levels 
 
B  LDH activity 
 
 
 
Figure 11. GSHEE in Neurons. Effects of BSO and GSHEE treatments on total GSH 
levels (A) and LDH activity (B) in neurons. Data are presented by the mean ± SEM.       
***, p<0.001. 
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A GSH levels 
 
B LDH activity 
 
Figure 12. GSHEE in astrocytes. Effects of BSO treatments and various concentrations 
of GSHEE on total GSH levels (A) and LDH activity (B) in astrocytes. Data are 
presented by the mean ± SEM.  ***, p<0.001. 
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6.3.1 Effect of GCEE on cultured astrocytes and neurons 
By contrast with GSHEE, 24-h treatment with 1mM GCEE did not increase 
significantly GSH levels in neither control nor BSO-treated neurons (figure 13A). As 
assessed by measuring the activity of LDH from culture media, cell viability was 
affected neither by BSO nor by GCEE treatment (figure 13B). 
However, 3mM GCEE was efficient in raising GSH levels in BSO-treated astrocytes to 
levels similar to those observed in controls (p< 0.001; figure 14A). 1mM or 2mM 
GCEE only partially increased GSH levels in a dose-dependant manner. Treating 
control astrocytes with 1mM, 2mM or 3mM GCEE, did not lead to any significant 
increase in GSH levels. As assessed by the measurement of the activity of LDH from 
culture media, cell viability was not affected neither by BSO nor by GCEE treatment 
(figure 14B). 
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A GSH levels 
 
B GCL activity 
 
Figure 13. GCEE in neurons. Effects of BSO and GCEE treatments on total GSH 
levels (A) and LDH activity (B) in neurons. Data are presented by the mean ± SEM.         
**, p<0.01; ***, p<0.001. 
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A  GSH levels
 
B GCL activity 
Figure 14. GCEE in astrocytes. Effects of BSO treatments and various concentrations 
of GCEE on total GSH levels (A) and LDH activity (B) in Astrocytes. Data are 
presented by the mean ± SEM. **, p<0.01; ***, p<0.001. 
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5.3.3 Effect of GSH replenishment on NMDA response 
The effect of a deficit in GSH in neurons on NMDA-mediated calcium responses 
(NMDA response) was assessed (figure 15). There was no difference between NMDA 
responses in control and BSO-treated neurons. We then investigated whether a GSH 
deficit affected the modulation of NMDA responses by dopamine. Superfusion of 
dopamine (1 min, 1µM) changed the magnitude of NMDA responses; this modulation 
of NMDA responses was different in BSO-treated and in control neurons. There were 
significant effects of BSO treatment (p < 0.001) and a significant interaction between 
BSO treatment and dopamine (p < 0.001) as revealed by a Scheirer-Ray-Hare two-way 
ANOVA performed on NMDA responses. When GSH deficit was induced, the presence 
of dopamine, significantly decreased NMDA responses compared to NMDA responses 
measured in the absence of dopamine in BSO-treated neurons (p < 0.01) and in the 
presence of dopamine in control neurons (p < 0.001). 
Treatment with 1mM GSHEE significantly increased GSH contents in BSO-treated 
neurons to levels similar to those measured in control neurons (figure 11A). We 
therefore investigated whether restoring GSH levels in BSO-treated neurons would 
abolish the dopamine-induced decrease of NMDA responses. When GSH levels were 
increased with GSHEE in BSO-treated neurons, dopamine no longer decreased NMDA 
responses (figure 15). Indeed, GSHEE significantly increased NMDA responses of 
BSO-treated neurons under dopamine superfusion compared to BSO-treated neurons in 
the absence of GSHEE (p < 0.01). These results demonstrate that a depletion of 
intracellular GSH was responsible for the dopamine-induced decrease of NMDA 
responses observed in BSO-treated neurons. It also showed that GSHEE can remediate 
to the deleterious effect of a blockade of GSH synthesis on NMDA-dependent calcium 
responses. 
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Figure 15. Effects of BSO-induced GSH deficit on dopamine modulation of NMDA 
responses (n = 91-115) and effects of re-establishment of GSH levels with GSHEE on 
that modulation (n = 120-122). Data are presented by the median and quartiles.           
**, p<0.01; ***, p<0.001. 
6. Strategy 2: Boosting the rate-limiting enzyme GCL    
On section 5, we saw that is it possible to increase GSH levels using substances that 
bypass GCL, the enzyme that is responsible for the deficit in GSH observed in 
schizophrenia patients (Gysin et al., 2005;Tosic et al., 2006). GCLM and GCLC being 
two phase II genes, we hypothesized that it would be possible to increase their 
expression using substances known to induce these genes. To test this strategy, 
curcumin (polyphenol), quercetin (flavonoid), tert-butylhydroquinone (quinone) and 
FK506 (immunosuppressant) were used (table 1). GSH acts as an antioxidant via the 
enzyme GST and, via the redox cycle, acts as a free radical scavenger (Pias and Aw, 
2002). The effects of the substances on the redox status inside the cells, was assessed 
via the measurements of both GSH and GSSG levels. The actvity of GST was measured 
in order to observe a potentatial activation of the transferase pathway, by which GSH 
plays its antioxidant role. Of course, since the main idea is to boost GCL, the activity of 
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this enzyme was measured, as well as the cell viability. Furthermore, in an attempt to 
better understand the mechanisms by which they could produce their effects, we 
measured the expression of genes implicated in GSH metabolism: the transcription 
factors Nrf2, the two subunits of the cysteine-glutamate exchanger, xCT and 4F2, the 
two subunits of GCL, GCLM and GCLC, as well as GSS and GPx. All these 
measurements were done in both astrocytes and neurons. Finally, because of the 
evidence suggesting a link between GCLM and schizophrenia, we assessed the 
necessity of a functional GCLM in the action of the substances used. This was done 
using astrocytes from GCLM KO mice. 
 
Table 1. Cell types in which curcumin, quercetin, tBHQ and FK506 could increase GSH 
levels, and proposed mechanisms underlying this increase. 
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6.1 Introduction 
6.1.1 Curcumin 
Diferuloylmethane [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], 
commonly named curcumin (figure 16), is a polyphenol extracted from turmeric, the 
powdered rhizome of the plant, Curcuma longa, which is part of the Zingiberaceae 
family that also include ginger. This yellow-colored spice is widely used by Asians in 
the preparation of curry. Curcumin has been the subject of hundreds of papers over the 
past three decades, studying its antioxidant, anti-inflammatory, cancer chemopreventive 
and potentially chemotherapeutic properties.  
Figure 16. Curcumin 
Curcumin was shown to increase GSH in different cell lines, such as cultured human 
erythroleukemia (K562; Singhal et al., 1999), type 1 astrocytes from rat (DI TNC1; 
Scapagnini et al., 2002), human bronchial epithelial (HBE1; Dickinson et al., 2003), 
human myelomonocytes (U937; Strasser et al., 2005) and human alveolar epithelial 
(A549; Biswas et al., 2005). This increase in GSH levels could be due to an increase of 
de novo GSH synthesis following the increased activity of GCL due to an induction of 
its expression by Nrf2. Indeed, curcumin was shown to increase Nrf2 protein levels in 
nuclear extracts from rat type 1 astrocytes (DI TNC1) and Nrf2 translocation to the 
nucleus was accompanied by an upregulation of some phase II enzymes in these cells 
(Scapagnini et al., 2006). In human lung epithelial cell lines, an increase in the content 
of GCLC (Biswas et al., 2005) and GCLM mRNA, as well as in the content of both 
GCL subunit proteins was observed after a treatment with curcumin (Dickinson et al., 
2003). Finally, curcumin induced 1.6 fold increase in GCL activity in K-562 cells 
leading to a 1.2 fold increase in GSH levels (Singhal et al., 1999). 
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6.1.2 Quercetin 
Flavonoids are polyphenolic compounds that include more than 6 000 naturally 
occurring substances that can be found in every parts of a plant. They are responsible 
for the color of many fruits, vegetables and flowers. Thus, we can find flavonoids in tea, 
fruits and vegetables as well as in red wine. Flavonoids possess a skeleton made of 15 
atoms of carbon arrange in two aromatic rings linked by a linear chain of three carbons. 
Seven major subgroups can be found in most major plants: chalcones, flavones, 
flavonols, flavandiols, anthocyanins condensed tannins and aurones (Winkel-Shirley, 
2001). Subsequent steps, in particular glycosylation and acylation, bring flavonoids to 
their definitive structure that can be found in vivo. Like GSH, flavonoids possess 
antioxidant properties, as well as the capacity to eliminate free radicals. These attributes 
made flavonoids responsible for the well know phenomenon named “French paradox”. 
In spite of a high risk factor to develop conditions like cholesterol, diabetes, 
hypertension due to a high ingestion of saturated fatty acid, French peoples show the 
lowest mortality from coronary heart disease among industrialized occidental countries 
(Renaud and de Lorgeril, 1992). It is possible that this paradox could be explained by 
the regular red wine consumption in France (Renaud and Gueguen, 1998).  
During an oxidative stress, GSH levels decrease, ROS levels increase and that is 
accompanied by a massive entrance of calcium Ca2+ in the cell, followed by cell 
apoptosis (Tan et al., 1998). Therefore, substances that protect cells against oxidative 
stress can act at various levels, either by increasing GSH levels, neutralizing ROS or 
preventing the massive Ca2+ entrance. Flavonoids were classified into three categories 
according to the protection mechanism they use (Ishige et al., 2001).  Thus, during a 
glutamate-induced toxicity in neurons, “flavonoles” type maintain low Ca2+ levels in 
spite of the presence of ROS and the decrease in GSH levels. “Galanguines” neutralize 
ROS and at last, “quercetines”, in addition to the fact that they neutralize ROS, also lead 
to an increase in GSH levels. We were therefore interested in the main representative of 
that very last type of flavonoids, the quercetin itself (figure 17). Quercetin can be found 
in onions, apples, green or black tea and, in lowest amount, in green leaves vegetables 
and beans. In addition to its antioxidant properties, quercetin is known for its 
antihistaminic, anticancer, anti-inflammatory, antiviral and antibacterial properties. 
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Figure 17. Quercetin 
Quercetin induced an increase of GSH levels in human breast cancer cells (MCF7; 
Rodgers and Grant, 1998), monkey kidney derived cells (COS-1; Myhrstad et al., 2002), 
human hepatoma cell line (HepG2; Alia et al., 2005;Scharf et al., 2003). The proposed 
mechanism for the increase in GSH levels by quercetin is the upregulation of the 
enzyme GCL linked, via the activation of Nrf2 and induction of phase II genes (figure 
5). Indeed, it was shown that quercetin is able to induce the ARE-dependent gene, 
NAD(P)H:quinone oxidoreductase (NQO1; Valerio et al., 2001). More specific to our 
purpose, the increase in GSH levels in COS-1 cells was accompanied by an increase in 
GCLC and GCLM mRNA levels (Myhrstad et al., 2002). 
6.1.3 tert-Butylhydroquinone 
tert-Butylhydroquinone (tBHQ) is a xenobiotic, meaning that this substance is not 
endogenous. It is a synthetic phenolic antioxidant used as a model inducing agent for 
ARE-driven transcription (Nguyen et al., 2003). tBHQ is the metabolite of butylated 
hydroxyanisole, both substances being used as food preservative for their antioxidant 
properties.  
tBHQ increased GSH levels in HBE1 (Krzywanski et al., 2004) and HEPG2 (Galloway 
et al., 1997) and this was preceded by an increase in both GCLC and GCLM mRNA, but 
only GCLC protein levels were increased (Krzywanski et al., 2004). It was also shown 
to increase GSH levels in astrocytes following the activation of the transcription factor 
Nrf2 (Lee et al., 2003;Sun et al., 2005;Vargas et al., 2006). In another study, tBHQ also 
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increased GSH levels in mice cortical astrocytes, but not in neurons (Eftekharpour et al., 
2000), suggesting that phase II enzymes can be induced in astrocytes, but with 
considerably lower levels in neurons (Ahlgren-Beckendorf et al., 1999;Eftekharpour et 
al., 2000;Shih et al., 2003). 
 
Figure 18. tert-Butylhydroquinone 
6.1.4 FK506 
FK506, also named tacrolimus, is an immunosuppressant widely used for organ 
transplants. This substance is isolated from the microscopic fungus Streptomyces 
tsukubaensis (Vinet and Busque, 1997). The majority of research on immunophilins, the 
receptors for FK506, has focused on cells of the immune system, but the finding that the 
immunophilins are much more abundant in the nervous system led to researches that 
revealed important roles for the immunophilins in multiple areas of neural function. 
These include regulation of nitric oxide (NO) neurotoxicity, neurotransmitter release, 
intracellular Ca2+ flux via the ryanodine and the inositol-(1,4,5)-trisphosphate (IP3) 
receptors, as well as neurotrophic influences (Snyder et al., 1998). 
GSH levels were shown to be increased after FK506 treatment in neuroblastoma cell 
line (Neuro 2A; Tanaka et al., 2000), in neuroblastoma-glioma hybrid cell line (NG108-
15; Tanaka et al., 2001), and in glioma cell lines (C6, U251; Tanaka et al., 2002;Tanaka 
et al., 2004). However, the mechanisms by which this immunosuppressant can increase 
GSH levels are unclear. The same group has conducted an in vivo study during which 
FK506 was i.p.-injected to mice and they observed an increase in GSH levels in 
striatum, as well as an increase in gene expression of GCL. However, no distinction was 
done between the whole GCL and its subunits, regarding the mRNA quantification, 
which it quite intriguing. No change in mRNA levels of GPx or GST was observed, 
leading one to doubt about the phase II enzyme-induction activity of FK506. 
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Furthermore, in astrocytes depleted in GSH by BSO, another group has observed an 
increase in GSH levels after FK506 treatment (Gabryel et al., 2005). BSO being an 
inhibitor of GCL, the action of FK506 is most probably not through the activation of 
this enzyme. It is proposed that the antioxidant properties of FK506 themselves prevent 
the decrease in GSH levels (Nishinaka et al., 1993).  
 
Figure 19. FK506 
6.2 Materials and methods 
6.2.1 Primary cultures of cortical neurons 
Cultures of cortical neurons were prepared from E16-17 OF1 mice (S/IOPS OF1 from 
Charles River Laboratories, L’Arbresle, France) and from C57BL/6 GCLM knock out 
mice (provided by Timothy P. Murphy, Department of Environmental Health, Center 
for Environmental Genetics, Cincinnati, OH and bred in our animal facility) in 
accordance with the authorization issued by the “Office Vétérinaire du Canton de 
Vaud”. The pregnant female mouse was decapitated, brains of embryos were removed 
and cortices were isolated in Hanks’ balanced salt solution (137mM NaCl, 5.3mM KCl, 
0.45mM KH2PO4, 0.34mM Na2HPO4, 4.16mM NaHCO3, 5.5mM glucose, 1mM sodium 
pyruvate, pH = 7.4) containing penicillin (100 U/ml) and streptomycin (100µg/ml). 
Cortical cells were mechanically dissociated with a Pasteur pipette, centrifuged and 
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resuspended in Neurobasal medium (Invitrogen) supplemented with 2% B27 
(Invitrogen), 500µM glutamine and 30µM glutamate. GCLM KO female mice being 
unfertile, KO males were mated with heterozygote females to obtain KO and 
heterozygote fetuses. In these cases cortices dissected from fetuses could not be pooled 
and every brain had to be put in culture separately. Genotyping was done afterwards on 
animal’s skin. Neurons were plated on poly-L-ornithine-coated culture dishes at a 
density of 800 cells/mm2 or on poly-L-ornithine-coated glass coverslips at a density of 
600 cells/mm2. Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. 
6.2.2 Primary cultures of cortical astrocytes 
Cortices from P1-3 OF1 mice (S/IOPS OF1 from Charles River Laboratories, 
L’Arbresle, France) and C57BL/6 GCLM KO, heterozygotes (HZ) and wild-type (WT) 
mice were dissected in DMEM medium (Invitrogen, Carlsbad, CA, USA) supplement 
with 10% fetal bovine serum (Invitrogen) and containing penicillin (100 u/ml) and 
streptomycin (100µg/ml). Cortical cells were mechanically dissociated through needles 
with decreasing diameters, centrifuged at 500 rpm for 5 min and resuspended in the 
same supplemented DMEM medium. Astrocytes were harvested on poly-L-ornithine-
coated dishes and left to grow at 37°C in a humidified 5% CO2 atmosphere. 
6.2.3 Treatments 
Unless otherwise cited, four to six days-old neurons and 14-15 days-old astrocytes, 
either from OF1 or from GCLM KO, HZ and WT mice, were exposed for 24h to 
various concentrations of curcumin, quercetin, tBHQ or FK506 (figure 20). All 
substances were diluted in DMSO with a final percentage of DMSO lower than 0.09%. 
Cells were put in the presence of the substances following a medium renewal. New 
medium was made of Neurobasal supplemented with 500 µM glutamine and 2% B27 
without antioxidant and contained 5µM, 10µM, 20µM, 50µM or 100µΜ of substance or 
only DMSO as a control. These concentrations were chosen based on other in vitro 
studies using these compounds. For a given substance, treatments with the various 
concentrations and control were done on separate sister dishes. 
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 Figure 20. Experimental design 
6.2.4 Oxidized and reduced GSH measurement 
In order to assess the redox status in the cells, quantification of total GSH and oxidized 
GSH (GSSG) content in cells was performed with an assay based on the Tietze method 
(Tietze, 1969). Cells were washed twice with ice-cold PBS (150mM NaCl, 3mM KCl, 
1.5mM KH2PO4 and 7.9mM Na2HPO4), and scrapped out of the dish with 100 µl ice-
cold PBS containing 1-2.5mM EDTA. After sonication, an aliquot was reserved for 
subsequent analysis of protein content using the Advanced Protein Assay (Cytoskeleton, 
Denver, CO, USA). Proteins in the remaining cell solution were precipitated with 5-
Sulfosalicylic acid (SSA) and precipitate was removed from solution by centrifugation. 
Triethanolamine (TEA) was added to the supernatant to bring pH >7. For GSSG 
measurement, a part of the supernatant was incubated with 2-vinylpyridine monomer 
(2VP) for 45 to 60 minutes at room temperature. 2VP forms a stable complex with 
reduced glutathione. In a well of a 96-well plate, 100µl of supernatant diluted in PBS as 
much as needed, was mixed with 100 µl of freshly-made reaction solution [PBS with 
2.5mM EDTA, 0.3mM DTNB, 0.3mM NADPH and 1 U/ml GSH reductase]. The 
absorbance at 405 nm was measured with a plate reader 20 sec after mixing and then at 
15 sec intervals for 1 min. The rate of increase in absorbance, which measures the cyclic 
reduction of DTNB by GSH, was proportional to the total GSH or to the amount of 
GSSG when 2VP was added. Measurements were done in duplicates. Concentration of 
GSH and GSSG in sample solution was determined by comparison with a series of 
freshly-made GSH and GSSG standard solutions respectively. Total GSH and GSSG 
content in cells are expressed in nmole GSH/mg proteins and nmole GSSG/mg proteins 
respectively. In order to better see the changes in GSSG relative to GSH, the percentage 
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of GSSG relative to GSH was calculated. In this case, GSH levels = total GSH levels – 
2 x GSSG levels. 
6.2.5 GCL activity measurements 
GCL activity was measured with an assay based on (White et al., 2003). One 10-cm 
dish was used per treatment for astrocytes, while 3 to 6 60-mm dishes were necessary 
for neurons. Cells were washed twice with ice-cold PBS, and scrapped out of the dish 
with ice-cold PBS containing 1mM EDTA. Cells were freezed at – 80°C until assay. 
After sonication, the cell solution was centrifuged at 14000 RPM for 15 min. An aliquot 
from the supernatant was reserved for subsequent analysis of protein content using the 
Advanced Protein Assay. On a 96-well round bottom reaction plate, 50 µl of cell 
solution was put into eight wells, four of which already contained 5 µl of 40mM BSO. 
Plate was preincubated at 37°C for 15 min. 50 µl of reaction cocktail [stock solution 
made of : 400mM Tris, 20mM L-glutamic acid, 2mM EDTA, 20mM sodium borate, 
2mM serine, plus 40mM ATP added freshly] was then added to each well. Five min 
later, reaction was initiated by adding 2mM cysteine [diluted in a stock solution made 
of: 20mM Tris, 1mM EDTA, 250mM D(+)-sucrose, 20mM sodium borate and 2mM L-
serine]. The plate was then covered and incubated at 37°C for 45 min, time during 
which cysteine is linked to glutamine via GCL to form γ-glucys. The reaction was 
stopped when 200mM SSA was added to all wells and the plate was centrifuged for 5 
min at 1200 g. 20 µl of supernatant from each well was transferred to a 96-well plate 
designed for fluorescence detection. A series of wells also contained various 
concentrations of freshly made GSH solution for standard curve. 200 µl of 10mM NDA 
solution was added to all wells [NDA was diluted in DMSO and 1 vol was added to 8 
vol of a stock solution made of: 50mM Tris and 500mM NaOH, pH 12.5]. NDA forms a 
conjugate with the cysteine sulfhydryl group and the glutamyl amino group of γ-glucys 
and of GSH with the same affinity. After 30-min incubation at room temperature, 
fluorescence was measured with an excitatory wavelength of 485nm and an absorbance 
filter set to 530nm. No glycine was added to the reaction mix, so measured fluorescence 
is related to the levels of γ-glucys. Since equimolar of GSH and γ-glucys give similar 
NDA fluorescence, we used GSH for standard curves. Basal GSH levels measured in 
the well where GCL was blocked with BSO were subtracted to the values obtained 
where GCL was active. GCL activity is expressed in nmol GSH/mg proteins/min. 
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6.2.6 GST activity measurements 
Total GST activity was assessed by measuring the conjugation of CDNB with reduced 
GSH (Habig et al., 1974), such a conjugation depending on GST. Cells were washed 
twice with ice-cold PBS, and scrapped out of the dish with ice-cold potassium 
phosphate buffer (PPB; pH 6.5) containing 2mM EDTA. After sonication, the cell 
solution was centrifuged at 14000 RPM for 15 min. Supernatant was freezed at – 80°C 
until assay. Once unfrozen, an aliquot from the supernatant was reserved for subsequent 
analysis of protein content using the Advanced Protein Assay. On a 96-well plate, 20 µl 
of cell solution was diluted into PPB containing 0.1% Triton. Freshly-made GSH was 
also added for a final concentration of 1mM in well. The reaction was initiated by 
adding CDNB and the absorbance was red at 340nm every 15 sec for 5 min. 
Measurements were done in triplicates. Activity of GST in sample solution was 
determined by comparison with a series of freshly-made GST standard solutions. The 
possible presence in samples of the substance used in the treatment did not interfere 
with the measurements of GST as verified using standard solutions of the various 
substances. GST activity in cells is expressed in U/mg proteins. 
6.2.7 Gene expression 
After 8-h or 18-h treatment, mRNA levels were measured in cultured neurons and 
astrocytes, with the use of TaqMan chemistry. mRNA was first extracted from samples 
with an RNA isolation kit (Promega, Madisson, WI, USA). Total mRNA was quantified 
using Ribogreen Assay kit (Invitrogen, Carlsbad, CA, USA) and 300 ng of total RNA 
was reverse-transcribed to cDNA. This cDNA was then amplified using TaqMan gene 
expression assays (Applied Biosystem, Foster City, CA, USA) at the following 
amplification condition: 1 cycle for 2 min at 50°C, 1 cycle for 10 min at 95°C, and 50 
cycles for 15 s at 95°C, followed by 1 min at 60°C. The following genes were 
amplified: Gclm (Applied Biosystem, Mm00514996_m1), Gclc (mM00802655_m1), 
Gpx1 (Mm00656767_m1), Gss (Mm00515065_m1), Nrf2 (Mm00477784_m1), Nrf3 
(Mm00477788_m1), xCT (Mm00442530_m1) and 4F2 (Mm00500521_m1). Mouse 
18S ribosomal protein (4319413E) was used as endogenous control. cDNA of treated 
sample was amplified again from original mRNA when the number of cycle to reach 
treshold (Ct) for 18S was different between treated and control samples on a same plate. 
Measurements were done in duplicates. Gene expression was calculated using the ∆∆Ct 
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method (proposed by Applied Biosystem). ∆Ct, that is the difference between Ct of 18S 
subtracted from Ct of the gene of interest, is calculated from both the treated and the 
control samples. ∆Ct obtained with control is then subtracted from ∆Ct obtained from 
treatment sample and linearity is achieved with the expression 2- ∆∆Ct. The result 
obtained represents the amount of target gene in treated sample, normalized to an 
endogenous reference (18S) and relative to the control. 
6.2.8 Assessment of cell viability 
Cell viability was assessed by measuring the activity of lactate dehydrogenase (LDH) in 
the culture medium (adapted from Dringen et al., 1998). When cells are dying, cell 
membranes become permeable and cells release their content, including LDH, in the 
medium. An aliquot of culture medium was collected and kept at – 80°C. For 
measurement of LDH activity, 50 µl of the collected medium was mixed with 100 µl of 
0.1M potassium phosphate buffer (pH 7.4) and 150 µl of a freshly-made reaction 
solution [3.2mM sodium pyruvate and 0.4mM NADH in 0.1 M potassium phosphate 
buffer]. The decrease in absorbance at 340 nm, proportional to LDH activity, was 
recorded every minute for 10 min using a plate reader. Measurements were done in 
duplicates. LDH activity in the medium was scaled with the activity of a series of LDH 
standard solutions. The amount of LDH in the medium was then reported to the amount 
of proteins measured in the cells of the corresponding dish. 
6.2.9 Statistical analyses 
The potential effect of DMSO, in which all substances are dissolved, was assessed by 
comparing cells put in the presence of medium containing or not DMSO. For all the 
measurements, t-tests showed no differences between DMSO and no DMSO situations. 
Therefore, DMSO situation is considered as the control. The effect of treatments versus 
control on GSH and GSSG content, on GCL and GST activity, on gene expression and 
on cell viability was assessed with the t-test for dependant samples. Statistical 
significance was corrected for multiple comparisons using the sequential Bonferroni test 
with the Dunn-Šidák method (Sokal and Rohlf, 1997), when 4 or 5 different 
concentrations were used. One-way multivariate analysis of variance (MANOVA) with 
Concentration as dependent and Substance as independent variable, was used to assess 
the difference between the effects induced by the various substances. The concentration 
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5µM was not included in the analyses, since this concentration was not used during 
tBHQ treatments. The same analysis, with Concentration as dependent and Cell type as 
independent variable, was used to look at the effect of cell types. When significance 
was achieved, post-hoc comparisons were performed. To assess the differential effects 
of a treatment on the three different genotypes, two-way ANOVA was used, with 
Genotype and Concentration as between factor, followed by a paired comparison with 
LS-means correction. For the effect of treatments on cell death, LDH activity in 
medium from dishes containing the different genotypes was compared between 
genotypes with a t-test for independent samples. LDH activity in medium from treated 
sample was compared with a t-test for dependant samples with LDH activity in medium 
from untreated cells of the same genotype. Significant probability level was set to p  
0.05.  
6.3 Results 
6.3.1 Curcumin 
In neurons (figure 21), treatment with 5µM (p < 0.05), 10µM (p < 0.001), 20µM (p < 
0.05), 50µM (p < 0.01) or 100µM (p < 0.05) curcumin significantly increased GSH 
levels of about 50%. No significant change was observed in the percentage of GSSG 
relative to total GSH, although a trend in an increase could be observed with 100µM. 
Because of material limitation, GCL activity was measured only after treatment with 
10µM curcumin, concentration that was statistically the most efficient in increasing 
GSH levels. GCL activity was significantly increased of about 60% after this treatment 
(p < 0.05). No change in GST activity was observed, although a trend in an increase 
could be observed with 50µM (p < 0.05 before bonferonni correction). No increase in 
cell death was observed. Treatment with 10µM curcumin led to an increase in gene 
expression of xCT already after 8 hours and of the transcription factor Nrf2, the two 
subunits of the cystine-glutamate exchanger, xCT and 4F2, and the modulatory subunit 
of GCL, after 18h (table 2). The two genes that showed the greatest increase in their 
expression were GCLM and xCT. 
In astrocytes (figure22), treatment with 20µM (p < 0.001), 50µM (p < 0.001) or 100µM 
(p < 0.01) curcumin significantly increased GSH levels to as much as 125%. A trend 
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was already observed with 10µM (p < 0.05 before bonferonni correction). There was no 
change in the content of GSSG relative to total GSH. The increase in GSH levels was 
accompanied by an increase in GCL activity with 10µM (p < 0.05), 20µM (p < 0.05), 
50µM (p < 0.01) or 100µM (p < 0.05) curcumin. A significant decrease in GST activity 
was measured after treatment with 20µM (p < 0.05), 50µM (p < 0.05) or 100µM (p < 
0.05 before bonferonni correction). No increase in cell death was observed. 18-h 
treatment with 10µM curcumin slightly increased gene expression of GCLM and GSS, 
while a treatment with the same duration but with 50µM led to an increase in mRNA 
levels of the transcription factor Nrf2, the two subunits of the cystine-glutamate 
exchanger, xCT and 4F2, the two subunits of GCL, GCLC and GCLM, and the second 
synthesizing enzyme of GSH, GSS (table 2). Like in neurons, the two genes that 
showed the greatest increase in their expression were GCLM and xCT, but increase in 
GSS mRNA was also important in astrocytes.  
MANOVA on GSH levels data with Concentration as dependent variable showed a 
significant effect of cell type with 50µM curcumin (p = 0.01), meaning that the increase 
in GSH levels observed in astrocytes is significantly more important than in neurons. 
See figure 23 for a summary of the results obtained following 24-h treatment with 
curcumin in cultured astrocytes and neurons. 
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Figure 21. Curcumin in neurons. Effect of curcumin on GSH (n = 4 to 12) and GSSG 
(n = 3 or 4) levels, GCL (n = 7) and GST (n = 4 or 5) activity, and cell death (n= 12 to 
14) in neurons. Data are expressed as percentage of change relative to control ± SEM.  
*, p<0.05; **, p<0.01; ***, p<0.001.  
 
Figure 22. Curcumin in astrocytes. Effect of curcumin on GSH (n = 10 or 11) and 
GSSG (n = 5) levels, GCL (n = 4 to 7) and GST (n = 4) activity, and cell death (n= 12 to 
13) in astrocytes. Data are expressed as percentage of change relative to control ± SEM. 
(*), p<0.05 before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
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Table 2. Effect of curcumin on gene expression in neurons and astrocytes. Results 
represent the amount of target gene in treated sample, normalized to an endogenous 
reference (18S) and relative to the control. p<0.05, 0.05 < p < 0.01. 
 
Figure 23. Summary of the results obtained following 24-h treatment with curcumin in 
cultured astrocytes and neurons. Only significant changes are shown. 
 

"& 
"&"

 
#
!
!
γ%"
"
γ#
'(
"#
$


		



!
-
!
) !
-
!
"&-
2

 3
455. *5.
Concentration of curcumin 10µM 10µM 10µM 50µM
Duration of treatment 8h 18h 18h 18h
Number of dishes n=3 n=6 n=4 n=5
nrf2 1.39 1.97 0.97 2.40
xCT 5.58 8.62 0.87 5.46
4F2 1.33 1.61 0.87 2.66
gclc 1.05 1.79 1.04 3.29
gclm 1.68 6.10 1.24 15.84
gss 0.87 1.81 1.29 5.62
gpx1 0.64 1.24 1.01 1.41
Neurones Astrocytes
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6.3.2 Quercetin 
In neurons (figure 24), treatment with low concentration of quercetin had no effect on 
GSH levels. Higher concentrations (50µM and 100µM) significantly decreased GSH 
levels (p < 0.01). Furthermore, cell death was significant with 50µM (p < 0.05) and 
nearly significant with 100µM (p < 0.05 before bonferonni correction), indicating a 
potential toxic effect of quercetin at high concentration in neurons. No significant 
change was observed in the percentage of GSSG relative to total GSH. Since quercetin 
did not succeed in increasing GSH levels in neurons, the effects of this substance on 
GCL and GST activity, and on mRNA levels were not evaluated.  
In astrocytes (figure 25), treatment with 10µM (p < 0.05), 20µM (p < 0.001), 50µM (p 
< 0.001) or 100µM (p < 0.01) quercetin significantly increased GSH levels of about 
50%. There was no change in the content of GSSG relative to total GSH. The increase 
in GSH levels was accompanied by an increase in GCL activity that was nearly 
significant with 5µM (p < 0.05 before bonferonni correction), and fully significant with 
10µM (p < 0.01), 20µM (p < 0.05) or 100µM (p < 0.01) quercetin. No change in GST 
activity and no increase in cell death were observed. 8-h treatment with 20µM quercetin 
increased gene expression of xCT and GCLM, and to a lesser extend GSS. 18-h 
treatment with the same concentration also led to an increase in mRNA levels of xCT, 
GCLM and GSS, but also those of GCLC (table 3). Like with curcumin treatment, 
mRNA levels that were increased the most with quercetin were those of GCLM and 
xCT. 
MANOVA on GSH levels data with Concentration as dependent variable showed a 
significant effect of cell type with 20µM (p < 0.001), 50µM (p < 0.001) and 100µM (p 
< 0.001) quercetin. Indeed these concentrations increased GSH levels in astrocytes, but 
not in neurons, where even a decrease was observed with the two higher concentrations. 
See figure 26 for a summary of the results obtained following 24-h treatment with 
quercetin in cultured astrocytes and neurons. 
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Figure 24. Quercetin in neurons. Effect of quercetin on GSH (n = 8) and GSSG (n = 4) 
levels, and cell death (n= 10 or 11) in neurons. Data are expressed as percentage of 
change relative to control ± SEM. (*), p<0.05 before correction; *, p<0.05; **, p<0.01; 
***, p<0.001. 
 
Figure 25. Quercetin in astrocytes. Effect of quercetin on GSH (n = 10 to 12) and 
GSSG (n = 5) levels, GCL (n = 5 to 7) and GST (n = 4) activity, and cell death (n= 11 to 
13) in astrocytes. Data are expressed as percentage of change relative to control ± SEM. 
(*), p<0.05 before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
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Table 3. Effect of quercetin on gene expression in astrocytes. Results represent the 
amount of target gene in treated sample, normalized to an endogenous reference (18S) 
and relative to the control. p<0.05, 0.05 < p < 0.01. 
 
Figure 26. Summary of the results obtained following 24-h treatment with quercetin in 
cultured astrocytes and neurons. Only significant changes are shown. 
6.3.3 Tert-Butylhydroquinone 
In neurons (figure 27), treatment with 10µM (p < 0.05) and 20µM (p < 0.01) tBHQ 
significantly increased GSH levels of about 20%. tBHQ had no effect, while 100µM 
significantly decreased GSH levels (p < 0.001). This decrease was accompanied by an 
Concentration of quercetin 20µM 20µM
Duration of treatment 8h 18h
Number of dishes n=4 n=4
nrf2 0,83 1,37
xCT 8,51 5,47
4F2 1,30 1,41
gclc 1,68 3,27
gclm 10,92 14,34
gss 2,05 3,70
gpx1 1,01 1,69
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increase in cell death that was already significant with 50µM (p < 0.05) and still 
observable with 100µM (p < 0.05). No significant change was observed in the 
percentage of GSSG relative to total GSH. Because of material limitation, GCL activity 
was measured only after treatment with 20µM tBHQ, concentration that was 
statistically the most efficient in increasing GSH levels. A trend in an increase of about 
40% in GCL activity was observed, but it was not significant probably due to the small 
sample. No change in GST activity and no increase in cell death were observed. 
Treatment with 20µM tBHQ led to an increase in gene expression of xCT with a trend 
for GCLM already after only 8 hours, and of Nrf2, xCT, 4F2, GCLC, GCLM and GSS 
after 18h (table 4). The genes that showed the highest increase in their expression were 
GCLM, xCT, and GSS. 
In astrocytes (figure 28), treatment with 20µM (p < 0.001), 50µM (p < 0.001) tBHQ 
significantly increased GSH levels of about 50%. This increase was nearly significant 
with 10µM (p < 0.05 before bonferonni correction), while no change was observed with 
100µM. At this concentration a trend in cell death was present (p < 0.05 before 
bonferonni correction). There was no change in the content of GSSG relative to total 
GSH, although a trend in an increase could be observed with 100µM. The increase in 
GCL activity was greater than that in GSH levels, with values as much as 150% higher 
than in controls. This increase was significant with 10µM (p < 0.01), 20µM (p < 0.01), 
50µM (p < 0.001) or 100µM (p < 0.01) tBHQ. No change in GST activity was 
observed. 8-h treatment with 100µM tBHQ slightly increased gene expression of GSS, 
but already had a huge effect on mRNA levels of xCT and GCLM. 18-h treatment with 
the same concentration led to an increase in mRNA levels of xCT, 4F2, GCLC, GCLM, 
GSS and GPX (table 3). Like in neurons, the genes that showed the highest increase in 
their expression were GCLM, xCT, and GSS, with values as high as 20x to 40x higher 
relative to controls. 
MANOVA on GSH levels data with Concentration as dependent variable showed a 
significant effect of cell type with 100µM tBHQ (p = 0.006). Indeed, while GSH levels 
were increased in astrocytes, they were diminished in neurons. 
See figure 29 for a summary of the results obtained following 24-h treatment with 
tBHQ in cultured astrocytes and neurons. 
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Figure 27. tBHQ in neurons. Effect of tBHQ on GSH (n = 7 to 9) and GSSG (n = 3) 
levels, GCL (n = 4) and GST (n = 4) activity, and cell death (n= 10 to 13) in neurons. 
Data are expressed as percentage of change relative to control ± SEM. (*), p<0.05 
before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Figure 28. tBHQ in astrocytes. Effect of tBHQ on GSH (n = 9 to 12) and GSSG (n = 
5) levels, GCL (n = 6 or 7) and GST (n = 5) activity, and cell death (n= 14 to 17) in 
astrocytes. Data are expressed as percentage of change relative to control ± SEM.      
(*), p<0.05 before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
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Table 4. Effect of tBHQ on gene expression in neurons and astrocytes. Results represent 
the amount of target gene in treated sample, normalized to an endogenous reference 
(18S) and relative to the control. p<0.05, 0.05 < p < 0.01. 
 
 Figure 29. Summary of the results obtained following 24-h treatment with tBHQ in 
cultured astrocytes and neurons. Only significant changes are shown. 
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Concentration of tBHQ 20µM 20µM 100µM 100µM
Duration of treatment 8h 18h 8h 18h
Number of dishes n=3 n=5 n=5 n=4
nrf2 1,27 3,49 0,91 1,86
xCT 6,57 15,03 71,62 38,92
4F2 0,99 2,60 2,73 4,65
gclc 1,42 3,15 2,58 6,51
gclm 1,66 9,47 29,75 42,82
gss 1,14 5,10 4,62 20,46
gpx1 0,86 2,71 1,05 4,81
Neurones Astrocytes
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Statistical analyses allowing the comparison between substances were performed. In 
neurons, MANOVA on GSH levels data with Concentration as dependent variable 
showed a significant effect of substance. Treatment with curcumin was more efficient 
than tBHQ and quercetin in increasing GSH levels at a concentration of 10µM. At 
20µM and 50µM tBHQ was more efficient than quercetin, but curcumin was still the 
best treatment. Finally, with a concentration of 100µM, curcumin was still increasing 
GSH levels, while the two other substances led to a decrease in GSH levels. 
In astrocytes, the same analysis also showed a significant effect of substance, but only 
at a concentration of 50µM. Indeed, at this concentration, treatment with curcumin was 
more efficient than tBHQ and quercetin in increasing GSH levels. All three substances 
were equally efficient at other concentrations. 
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6.3.4 FK506 
In both neurons (figure 30) and astrocytes (figure 31), FK506 showed no capacity in 
increasing GSH levels, nor did it lead to cell death. No change in GSH levels being 
observed, this substances was not further investigated. 
 
Figure 30. FK506 in neurons. Effect of FK506 on GSH levels (n = 2) in neurons. Data 
are expressed as percentage of change relative to control ± SEM.  
 
Figure 31. FK506 in astrocytes. Effect of FK506 on GSH levels (n = 2 or 3) in 
astrocytes. Data are expressed as percentage of change relative to control ± SEM. 
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6.3.5 Effects of treatments in astrocytes from GCLM KO mouse 
The enzyme GCL is implicated in the pathophysiology of schizophrenia. The catalytic 
activity of the subunit GCLC is modulated by the subunit GCLM. Polymorphisms in the 
gene of the modulatory subunit of GCL (GCLM) was shown to be associated with 
schizophrenia in three different populations and GCLM gene expression is decreased in 
fibroblasts of patients (Tosic et al., 2006). After treatment with curcumin, quercetin and 
tBHQ, GCLM gene was always the most upregulated, stressing the importance of this 
subunit in the induction of GCL. The availability of the GCLM knockout mouse 
allowed us to investigate the necessity of this subunit in the action of the substances 
used. 
Figure 32 shows basal GSH levels in cultured neurons from wildtype (WT), 
heterozygous (HZ) and GCLM knockout (KO) mice. No significant difference in GSH 
levels could be measured between WT and HZ, while, in KO, these levels were 
decreased by 74% compared to WT (p < 0.001). However, no increase in cell death was 
measured in neurons from KO. Due to material limitation, basal GCL activity was not 
measured in these neurons and treatment with substances were done only in astrocytes. 
In astrocytes (figure 33 and 34), no significant difference in both GSH levels and GCL 
activity was observed between WT and HZ. Surprisingly, while GSH levels in KO were 
decreased by 80% compared to WT (p < 0.001), the 31% decrease in GCL activity was 
not significant. No increase in cell death was observed in astrocytes from KO. 
 
Figure 32. Basal GSH levels in neurons from GCLM WT (n=4), HZ (n=3) and KO mice 
(n=6). ***, p<0.001. 
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Figure 33. Basal GSH levels in astrocytes from GCLM WT (n=11), HZ (n=17) and KO 
(n=11) mice. ***, p<0.001.  
 
Figure 34. Basal GCL levels in astrocytes from GCLM WT (n=5), HZ (n=23) and KO 
(n=11) mice. 
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6.3.5.1  Curcumin 
In wild-type (WT), like in OF1 (figure 21), a trend in an increase in GSH levels was 
observed with 10µM curcumin and 50µM increased GSH levels by more than 125% (p 
< 0.001; figure 35A). This was accompanied by an increase in GCL activity that was 
significant only with a concentration of 50µM (figure 35B). Treatment with 50µM 
curcumin also increased GSH levels in HZ (p < 0.001; figure 35A), but significantly 
less than in WT (p < 0.01). Surprisingly, the increase in GCL activity induced by 50µM 
curcumin was significantly higher in HZ (200%; p < 0.001) compared to WT (120%; p 
< 0.05; figure 35B). This could just be due to the fact that the number of sample was 
higher in HZ (n=9) than in WT (n=5), leading to a higher variance in the last type of 
cells. In astrocytes from KO, neither 10µM nor 50µM could increase GSH levels and 
GCL activity (figure 35). Furthermore, treatment with 50µM led to significant cell death 
(p < 0.05). 
A  GSH levels        B  GCL activity 
 
Figure 35. Effect of curcumin on GSH levels (A; n=4 to 13), GCL activity (B; n=2 to 
17) and cell death (n=5 to 13) in astrocytes from GCLM WT, heterozygous and KO 
mice. *** or ***, p<0.001; compared to control of same genotype.  
*, p<0.05; **, p<0.01; ***, p<0.001; compared to other genotype after treatment with 
the same concentration. 
0 
50 
100 
150 
200 
250 
300 
350 
400 
+/+ +/- -/- 
45µ 
*5µ 
/0
!!

/
1
111
11
11 111
0 
50 
100 
150 
200 
250 
300 
 +/+  +/-  -/- .










!

-









!

$


)








	



45µ 
*5µ 
/0
!!

111
111
111
111
111
111
11
/
 61
6.3.5.2  Quercetin 
In WT, like in OF1 (figure 25), an increase in GSH levels of more than 50% was 
observed with 20µM quercetin (p < 0.001; figure 36A). This was accompanied by a 
200% increase in GCL activity (p < 0.001; figure 36B). Treatment with 20µM quercetin 
also increased GSH levels in HZ (p < 0.01; figure 36A). The increase in GCL activity 
induced by 20µM quercetin was equivalent to that observed in WT (p< 0.01; figure 
36B). In astrocytes from KO, 20µM quercetin treatment could not increase neither GSH 
levels, nor GCL activity (figure 36), but no cell death was observed at this 
concentration. 
A  GSH levels        B  GCL activity 
 
Figure 36. Effect of quercetin on GSH levels (A; n=3 or 4), GCL activity (B; n=3 or 4) 
and cell death (n= 3 or 4) in astrocytes from GCLM WT, heterozygous and KO mice. 
(*), p<0.05 before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
6.3.5.3  tBHQ 
In WT, like in OF1 (figure 21), a trend in an increase in GSH levels was observed with 
20µM tBHQ. With 100µM, GSH levels were increased by about 100% (p < 0.001; 
figure 37A), while at this concentration GSH levels were not increased anymore in OF1. 
Increase in GCL activity was significant only with a concentration of 100µM (p < 0.05; 
figure 37B). Treatment with 100µM tBHQ increased GSH levels (p < 0.001; figure 
37A) and GCL activity in HZ (p < 0.05). The trend in an increase of GCL activity with 
20µM tBHQ in both WT and HZ was not significant. In astrocytes from KO, neither 
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20µM nor 100µM tBHQ could increase GSH levels and GCL activity (figure 34). 
Furthermore, treatment with 100µM led to significant cell death (p < 0.05). 
A  GSH levels        B  GCL activity 
 
Figure 37. Effect of tBHQ on GSH levels (A; n=4 to 6), GCL activity (B; n=2 to 6) and 
cell death (n=4 to 6) in astrocytes from GCLM WT, heterozygous and KO mice. (*), 
p<0.05 before correction; *, p<0.05; **, p<0.01; ***, p<0.001. 
7. Strategy 3 : Providing more of the limiting precursor cysteine 
7.1 Introduction 
Schizophrenia patients present deficits in their evoked-related potentials measured with 
the EEG technique during oddball paradigms. During these paradigms, participants are 
presented with two stimuli, usually auditive or visual, that are characterized by different 
physical properties (e.g. different frequency or duration). The participant is required to 
discriminate between the two stimuli, thus eliciting early waves (P50, N100) that are 
associated with pre-attentive processes and later components (P300), reflecting 
cognitive function. The amplitude of the P300 was shown to be decreased in 
schizophrenia already 30 years ago (Roth and Cannon, 1972) and these results were 
repeated several times (for a review see Hansenne, 2000). There is increasing evidence 
that the pathophysiology of schizophrenia entails both high-level cognitive impairments 
as well as (and perhaps as a consequence of) low-level sensory processing deficits 
across sensory modalities (Butler and Javitt, 2005;Foxe et al., 2005;Javitt et al., 1999). 
Indeed, There is a large body of evidence suggesting that a significant proportion of 
patients with schizophrenia have sensory gating impairments as reflected by a decrease 
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in P50 amplitude (for a review see Potter et al., 2006). Furthermore, previous research 
has consistently shown that the mismatch negativity (MMN) is impaired in 
schizophrenia patients (Catts et al., 1995;Javitt et al., 1993;Javitt et al., 1998;Shelley et 
al., 1991;Shutara et al., 1996). The auditory MMN is defined as the differential response 
to deviant stimuli compared to distractors. It is a wave that appears around 100ms after 
the presentation of a deviant, attended or unattended, stimulus. MMN generation is 
thought to rely on intact NMDA receptor (NMDA-R) function. Indeed, NMDA-R 
antagonists block the generation of this wave in both primates (Javitt et al., 1996) and 
humans (Umbricht et al., 2000), suggesting that MMN reflects selective current flowing 
through open, unblocked NMDA channels. The amplitude of MMN is known to be 
decreased in schizophrenia, indicating an impaired NMDA-R activity in these patients. 
Interestingly, the greater the MMN impairment, the lower are the Global Assessment of 
Functioning Scale ratings, suggesting that MMN is linked to global impairments in 
everyday functioning in schizophrenia patients (Light and Braff, 2005).  
Several studies have demonstrated that the administration of NMDA-R antagonists, 
such as phencyclidine (PCP) or ketamine, to control subjects lead to the apparition of 
symptoms similar to those observed in schizophrenia and exacerbates these symptoms 
in patients (Krystal et al., 1994). It has been proposed that impairments in NMDA-R 
activity may contribute to the pathophysiology of schizophrenia (Coyle, 2006;Javitt and 
Zukin, 1991). The observed deficit in GSH in schizophrenia (Do et al., 2000) and the 
hypofunction of NMDA-R induced by low GSH (Steullet et al., 2006;Steullet et al., 
submitted), suggest that the dysregulation of the GSH system could be implicated in the 
reduced activity of NMDA-R in schizophrenia patients. Indeed, it was shown that GSH, 
as a reducing agent, can potentiate the activity of redox sensitive proteins, such as 
NMDA-R (Choi and Lipton, 2000;Kohr et al., 1994). 
We propose that, by increasing GSH levels in the brain of schizophrenia patients, 
various aspects of the cerebral function, reflected by MMN (Light and Braff, 2005), 
could be improved. Therefore, as a last strategy to increase GSH levels, more cysteine, 
which is the rate-limiting precursor in the synthesis of GSH (Meister et al., 1986), will 
be provided to schizophrenia patients.  
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7.1.1 NAC 
The free amino acid cysteine does not represent an ideal delivery system to the cell as it 
is potentially toxic and is spontaneously catabolized in the gastrointestinal tract and 
blood plasma. N-acetyl-cysteine (NAC) has therefore been used in various studies as a 
cysteine donor. Given orally, NAC is quickly absorbed and plasma peak concentration 
of cysteine are reached within 120 minutes (Borgstrom et al., 1986;Borgstrom and 
Kagedal, 1990;Olsson et al., 1988). NAC crosses the blood-brain barrier (Farr et al., 
2003) and cysteine can be used in the brain as GSH precursor. Indeed, animal studies 
have shown that systemic administration of NAC protects brain against GSH depletion 
(Aydin et al., 2002;Ercal et al., 1996;Fu et al., 2006;Kamboj et al., 2006). 
In the present study, NAC was used in an attempt to increase GSH levels in brain of 
schizophrenia patients. The effects of such GSH system modulation on the MMN as 
well as on the neuropsychological and biochemical status of schizophrenia patients were 
investigated.  
7.2 Methods 
7.2.1 Clinical trial 
NAC (1g 2x/day) and placebo were administered to schizophrenia patients in a double-
blind, cross-over design. One group received NAC for the first two months and then 
placebo for another period of two months, and the other group received placebo first 
and then NAC. NAC was purchased from Zambon (Italy). NAC and placebo capsules 
were manufactured by DFC Thompson (Sydney, Australia) and re-conditioned by a 
pharmacist of the Department of Psychiatry of the Centre Hospitalier Universitaire 
Vaudois and University of Lausanne. NAC being a precursor of GSH, we hypothesized 
that increasing brain levels of GSH in schizophrenia patients would improve cerebral 
functioning and in particular MMN generation. Electroencephalographic (EEG) 
recordings, and blood sampling were performed at the onset of the protocol (baseline 
measurements), at the point of cross-over, and at the end of the study. 
Psychopathological scales were evaluated every two weeks, according to the main trial 
protocol; the results of which are reported elsewhere (Berk et al., submitted). 
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7.2.2 Participants 
Eleven patients (9 men; 2 women; aged 31.9±3.4yrs.; mean±SEM) meeting DSM-IV 
criteria for schizophrenia were recruited from the ambulatory Schizophrenia Service of 
the Department of Psychiatry of the Centre Hospitalier Universitaire Vaudois by an 
experienced psychiatrist and a psychologist well-trained in Diagnostic Interview for 
Genetic Studies. The mean duration of illness was 9.4±2.5yrs. Data from these patients 
at the onset of the protocol were compared with those from eleven sex-matched and 
age-matched healthy controls (9 men; 2 women; aged 34.4±2.9yrs.), who were selected 
on the basis that they had never suffered from any psychiatric disorder.  
Table 5. Demographic and clinical characteristics of participants. 
Among the eleven patients, nine participated in the clinical trial and seven completed 
the entire study, including EEG recordings at cross-over and at the end of the study (see 
Table 5). The two patients who withdrew from the study reported that it was too 
demanding for them. Of the seven patients who completed the entire study, five were 
among the group that first received NAC and then placebo; the remaining two received 
placebo first and then NAC. As such, any effects observed during NAC administration 
are unlikely to follow simply from repeated task performance. Following their 
recruitment, patients were given an ID number, and both patients and investigators were 
blinded until the time of analysis, when data pooling necessitated unblinding. Patients 
and controls were recruited with fully informed written consent, and all procedures were 
approved by the Ethics Committee of the Faculty of Biology and Medicine of the 
University of Lausanne. All eleven patients and eight of the healthy controls were 
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interviewed with the Diagnostic Interview for Genetic Studies, developed by the NIMH 
(Nurnberger et al., 1994;Preisig et al., 1999). 
7.2.3 EEG Experimental paradigm 
During the EEG recordings, participants were presented with auditory pure tone stimuli 
(50ms duration; 10ms rise/fall time; 44.1kHz sampling rate; 70dB SPL at the ear) and 
performed a go/no-go oddball discrimination task. On the majority of trials (80%), the 
pitch was 1kHz, and on the remaining 20% it was 2kHz. Stimuli were presented 
binaurally via insert earphones (model ER-4P; Etymotic Research, Inc., Elk Grove 
Villlage, USA), and the inter-stimulus interval was 1.5sec. Participants were instructed 
to perform a button press upon hearing the 2kHz tone (deviant) and to withhold 
responses to the 1kHz tone (standard). Stimulus presentation and response recording 
were controlled by E-prime (Psychology Software Tools, Inc., Pittsburgh, USA). 
7.2.4 EEG recording and analyses 
Continuous EEG was recorded at 500Hz (baseline measurements) or 1000Hz (cross-
over and at the end of the protocol) through a 128-channel Geodesic Sensor Net system 
(Electrical Geodesics Inc., Eugene, OR) referenced to the vertex (Cz) and 100Hz low-
pass filtered. Electrode impedance was maintained below 50kΩ. Peri-stimulus epochs of 
continuous EEG (100ms before to 600ms after stimulus onset) were averaged from each 
participant separately for the two different stimuli (i.e. standards and deviants) to 
compute AEPs. Epochs with muscle activity, eye movements, or other noise transients 
exceeding ±100µV were automatically rejected off-line. Data from artifact electrodes 
were interpolated (Perrin et al., 1987), and AEPs were down-sampled to a common 121-
channel montage and baseline-corrected using the 100ms pre-stimulus period. AEPs 
were then recalculated to the common average reference and group-averaged. 
For baseline recordings, AEPs from control subjects were based on 316±24 
(mean±SEM) standard and 73±5 deviant stimuli, whereas those from patients were 
based on 590±57 standard and 148±14 deviant stimuli. Patients were presented with a 
larger number of stimuli to minimize the possibility that differences between 
populations followed from a lower signal-to-noise ratio in patients. The number of trials 
accepted in response to standard and deviant stimuli did not differ between recordings 
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during NAC and placebo treatments. Following NAC treatment, 726±39 standard and 
179±9 deviant trials were included. Following placebo treatment, 626±95 standard and 
164±18 deviant trials were included. 
Two separate series of AEP analyses were conducted. The first followed a between-
subjects design and was done in order to verify that our cohort of patients exhibited 
impaired MMN relative to healthy controls at the onset of the protocol, as has been 
repeatedly demonstrated in prior studies of schizophrenic patients (Catts et al., 
1995;Javitt et al., 1993;Javitt et al., 1998;Shelley et al., 1991;Shutara et al., 1996). The 
second followed a within-subjects design and was done in order to assess whether two 
months of NAC administration restored MMN generation relative to the administration 
of placebo. AEPs were analyzed following methods described in detail elsewhere that 
permit the examination of both local and global features of the electric field at the scalp 
(Murray et al., 2004). We briefly summarize these methods here.  
First, AEP components were identified using a topographic pattern analysis that is based 
on a modified atomize and agglomerate hierarchical clustering procedure as 
implemented in Cartool software (http://brainmapping.unige.ch/cartool.htm; see also 
Tibshirani et al., 2005). This clustering procedure identifies the topographies (i.e. maps) 
dominating the group-averaged AEPs across populations/conditions. The pattern 
observed at the group-average level was then statistically assessed at the individual 
participant level using a fitting procedure based on spatial correlation (Brandeis et al., 
1995; see also Murray et al, 2006 for a recent publication of formulae), yielding a 
measure of map presence. These values are then submitted to ANOVA, revealing 
whether and when different maps explain responses from different 
populations/conditions and by extension whether and when different configurations of 
underlying sources are active, because topographic changes forcibly follow from 
different configurations of underlying brain networks (Lehmann, 1987). As this analysis 
identified the same set and sequence of topographies in AEPs from both patient and 
control groups as well as all experimental conditions, we do not discuss it in detail in 
the Results. The main utility of the topographic pattern analysis in the present study was 
in identifying the onset and offset of AEP components according to topographic 
stability in time (see Results for details). In particular, we focus on the N1 component, 
which in all cases was identified over the 70-155ms interval, given the abundant 
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evidence that the MMN is contemporaneous with the N1. In addition to AEP 
waveforms at specific electrode locations (which were selected based on the N1 
topography), we also analyzed the strength of the electric field at the scalp using global 
field power (GFP) (Lehmann and Skrandies, 1980). GFP is equivalent to the root mean 
square across the electrode montage. AEP and GFP waveform area measures (vs. the 
0µV baseline) from each stimulus condition over the 70-155ms interval were compared 
between controls and patients at protocol onset, and between NAC and placebo 
treatments.  
7.2.5 Neuropsychological assessments and analyses 
We used a computerized neuropsychological tests battery focused on the cognitive 
functions known to be impaired in schizophrenia; including attention, memory, 
executive functions and binding capacities. Sustained attention was assessed with the 
Degraded Stimulus Continuous Performance Task (DS-CPT; Nuechterlein, 1991). The 
Span of Apprehension Test (SOA; Asarnow and Granholm, 1991) during which the 
patient has to detect the letters F and T among twelve other letters, was administered as 
a selective attention task. Reaction time was measured both during the AOP and during 
a simple button-pressing task, where the patient had to press a button as soon as a black 
circle appeared in the center of the screen. A subscale of the Wechsler Adult 
Intelligence Scale (WAIS), that is the digit recall, was used to assess working memory, 
and visuo-spatial working memory was measured with the Plane-Flightball Task 
(Cocchi et al., 2007). As a planification task, we used three computerized items of the 
Hanoï Towers, the first trial being a practice, while the second and third ones, more 
difficult, were used for the analyses. Intra-modal binding capacity (Singer, 
1995;Uhlhaas and Singer, 2006) was tested in a visual perception of shapes task (Parnas 
et al., 2001). These measures were assessed by a two-way, mixed effects ANOVA for 
crossover design with terms for Period (sequence), Patient and Treatment. The relevant 
effect of the treatment was adjusted for the random effect of the patient and for the 
study period (linked to the treatment sequence). 
7.2.6 Biochemical measurements and analyses 
GSH levels were measured in blood cells and GSH-related thiols, cysteine and 
cysteinyl-glycine, were measured in plasma. Blood was collected by venipuncture 
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between 7:00 and 8:30AM under restricted activity conditions and after fasting from the 
previous midnight. 18-20ml blood was collected in Vacutainer tubes coated with 
Ethylenediaminetetraacetic acid (Becton Dickinson, Franklin Lake, NJ). Hemoglobin 
was quantified before blood centrifugation for 5min at 3000g and 4°C. The pellet, 
corresponding to blood cells, was washed twice with 0.9% NaCl and frozen at –80°C 
until analyses. The supernatant, corresponding to the plasma, was sampled in aliquots 
and kept at –80°C until analyses. Total GSH in blood cells was determined using a 
diagnostic kit purchased by Calbiochem (EMD Biosciences Inc, Darmstadt, Germany) 
and is expressed in µmol GSH per ml of blood. The method is based on a colorimetric 
assay of a chromophoric thione formed specifically between the reagent and GSH. Total 
cysteine and cysteinyl-glycine were quantified in plasma with a technique adapted 
from(Jacobsen et al., 1994). Briefly, thiols were reduced and/or decoupled from proteins 
by reaction with Tris (2-carboxyethyl) phosphine(Krijt et al., 2001). After 
deproteinization with perchloric acid, thiols were derivatized with 7-
fluorobenzofurazane-4-sulfonic acid (SBD-F). SBD-F derivates were analyzed by 
HPLC followed by fluorometric detection. Concentrations are expressed in µmol/l. 
From blood samples, analyses were primarily focused on GSH levels in blood as well as 
on levels of precursors: cysteine, one of the substrates of GCL, and cysteinyl-glycine, 
the product of GCL. These measures were assessed by a two-way, mixed effects 
ANOVA for crossover design with terms for Period (sequence), Patient and Treatment. 
The relevant effect of the treatment was adjusted for the random effect of the patient 
and for the study period (linked to the treatment sequence). 
7.3 Results 
7.3.1 Patients differ from controls at baseline 
7.3.1.1  Behavioral results 
Reaction times on the auditory discrimination task did not differ between patients 
(mean±SEM: 772±45ms) and healthy controls (610±77ms). Likewise, performance 
accuracy was near ceiling levels for both groups (patients: 98±1%; controls: 100±0%). 
This pattern of results thus argues against differences in selective attention or task 
performance as underlying AEP differences between groups.  
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7.3.1.2  Electrophysiological results 
The topographic pattern analysis identified the same sequence of maps in both 
populations and thus provided no evidence for differences in the configuration of 
underlying brain networks either between conditions or populations. The results of that 
analysis will therefore not be discussed further. However, this method of defining AEP 
components provided a more objective means for defining time periods for the analysis 
of AEP and GFP waveforms. Likewise, the topography of the AEP (i.e. the location of 
peak amplitude) was used for the selection of specific scalp electrodes for the analysis 
of AEP waveforms. The N1 component of the AEP was identified over the 70-155ms 
interval. 
AEP waveforms from four fronto-central electrodes are displayed in Figure 38a. Visual 
inspection of these waveforms indicates that healthy controls showed an early 
differential response (i.e. the MMN) between standard and deviant stimuli, whereas 
patients did not. This pattern is in keeping with what would be expected from prior 
investigations of the MMN in schizophrenia patients (Catts et al., 1995;Javitt et al., 
1993;Javitt et al., 1998;Shelley et al., 1991;Shutara et al., 1996). To statistically assess 
whether our cohort of patients exhibited a deficient MMN, area measures (vs. the 0µV 
baseline) were taken from these electrodes over the 70-155ms interval and submitted to 
a 2x2x4 repeated measures ANOVA, using diagnosis for schizophrenia as the between 
subjects factor and stimulus condition and electrode as within subjects factors. 
Importantly, there was a significant interaction between diagnosis for schizophrenia and 
stimulus condition (F(1,20)=11.605; p=0.003). Given this interaction, we then quantified 
the MMN for each population by calculating the average difference between responses 
to standard and deviant stimulus conditions across the 4 electrodes (bar graph in Figure 
1a). These values were then submitted to a one-way ANOVA using diagnosis for 
schizophrenia as the between subjects factor. As expected, the MMN amplitude was 
significantly smaller in patients than in controls (F(1,20)=11.626; p=0.003). An identical 
pattern of results was evident in the GFP waveforms (Figure 38b), which represent a 
global measure of the AEPs across the entire electrode montage and therefore are not 
influenced by a pre-selection of specific electrodes for analyses. GFP area measures (vs. 
the 0µV baseline) over the 70-155ms interval were submitted to a 2x2 repeated 
measures ANOVA, using diagnosis for schizophrenia as the between subjects factor and 
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stimulus condition as the within subjects factor. As above, there was a significant 
interaction between diagnosis for schizophrenia and stimulus condition (F(1,20)=6.629; 
p=0.018). We then directly analyzed MMN amplitude with a one-way ANOVA, which 
revealed a significantly smaller MMN for patients than for controls (F(1,20)=6.641; 
p=0.018; bar graphs in Figure 38b). Thus, analyses both at the level of single electrodes 
and also at the level of the global electric field strength confirmed that the MMN was 
deficient in our group of patients at protocol onset. 
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Figure 38. Electrophysiological responses at protocol onset from schizophrenia patients 
and healthy controls. a. The upper panels display exemplar AEP waveforms (voltage as 
a function of time) from a selection of fronto-central scalp locations (see inset for 
precise locations) in response to standard and deviant stimuli in both populations (color 
scheme indicated). Of particular interest is the initial negative-going component when a 
MMN is typically observed in healthy controls. The bar graph illustrates the group-
averaged MMN (±SEM) during the 70-155ms post-stimulus period and averaged across 
the above scalp locations. b. GFP waveforms from all stimulus conditions and MMN 
magnitude are displayed for schizophrenia patients and healthy controls. Conventions 
are identical to those in a. 
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7.3.2 NAC increases MMN in schizophrenia patients 
7.3.2.1  Behavioral results 
Reaction times on the auditory discrimination task did not differ between patients 
following NAC (mean±SEM: 800±17ms) and placebo treatment (829±30ms). Likewise, 
performance accuracy was near ceiling levels for both treatments (NAC: 100±0%; 
placebo: 97±3%). This pattern of results thus argues against differences in selective 
attention or task performance as underlying AEP differences between treatments. 
7.3.2.2  Electrophysiological results 
As was the case at protocol onset, the topographic pattern analysis identified the same 
sequence of maps in response to both treatments and stimulus conditions. Thus, there 
was no evidence for differences in the configuration of underlying brain networks with 
NAC treatment or between stimulus conditions. The results of this analysis will 
therefore not be discussed further. The N1 component of the AEP was identified over 
the 70-155ms period, and the sequence of group-average AEP response topographies 
over the 80-120ms interval are displayed in Figure 39 for each treatment and stimulus 
condition. A fronto-central negativity was observed across both NAC and placebo 
treatments and both stimulus conditions. Inspection of the topography of the difference 
between stimulus conditions suggests that there was a robust MMN following NAC but 
not placebo treatment. 
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Figure 39. Topographic maps of AEP responses showing the distribution of voltage 
amplitude across the scalp at 10ms intervals from 80-120ms post-stimulus onset. Panels 
a and b show responses following NAC and placebo treatment, respectively, for each 
stimulus condition as well as their difference (i.e. the MMN).  
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AEP waveforms from four fronto-central electrodes are displayed in Figure 3a and 
suggest that N1 responses to deviant sounds were stronger following NAC than placebo 
treatment (red and blue traces, respectively), whereas responses to standard sounds did 
not differ (black and green traces, respectively). Area measures (vs. the 0µV baseline) 
were taken from these electrodes over the 70-155ms interval and submitted to a 2x2x4 
repeated measures ANOVA, using treatment, stimulus condition, and electrode as the 
within subjects factors. The main effect of treatment did not reach the 0.05 significance 
criterion (F(1,6)=0.739; p=0.423), providing no evidence for a global change in AEP 
amplitude with NAC treatment. There was a significant main effect of stimulus 
condition (F(1,6)=21.206; p=0.004), following from the generally stronger responses to 
deviant than to standard stimulus conditions. Most critically, there was a significant 
interaction between treatment and stimulus condition (F(1,6)=8.799; p=0.025; 
p
2
=0.595). Given this interaction, we then quantified the MMN for each treatment by 
calculating the average difference between responses to standard and deviant stimulus 
conditions across the 4 electrodes (bar graph in Figure 3a). These values were then 
tested with a paired t-test and were significantly larger following NAC than placebo (-
31.3±7.1µV vs. -7.5±4.2µV, respectively; t(6)=2.966; p=0.025). An identical pattern of 
results was evident in the GFP waveforms (Figure 3b). GFP area measures (vs. the 0µV 
baseline) over the 70-155ms interval were submitted to a 2x2 repeated measures 
ANOVA, using treatment and stimulus condition as the within subjects factors. As 
above, there was a significant main effect of stimulus condition (F(1,6)=20.562; p=0.004) 
and a significant interaction between treatment and stimulus condition (F(1,6)=6.141; 
p<0.05; p2=0.506). We then directly analyzed MMN amplitude with a paired t-test, 
which revealed a significantly larger MMN following NAC than placebo (27.1±6.1µV 
vs. 12.7±4.2µV, respectively, t(6)=2.458; p<0.05; bar graphs in Figure 3b). Thus, 
analyses at the level of single electrodes and also at the level of the global electric field 
strength confirmed that the MMN was improved following NAC but not placebo 
treatment. We would note that all but one of the patients exhibited an enhanced MMN 
while receiving NAC relative to when receiving placebo treatment. 
We also examined whether the later P300 component was modulated by whether or not 
patients were receiving NAC or placebo. For this analysis GFP area measures were 
calculated over the 235-600ms interval (see waveforms in Figure 3b), using the 
abovementioned topographic pattern analysis as a basis for the identification of AEP 
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Figure 40. Electrophysiological responses following NAC and placebo treatment. a. The 
upper panels display exemplar AEP waveforms (voltage as a function of time) from a 
selection of fronto-central scalp locations (see inset for precise locations) in response to 
standard and deviant stimuli after each type of treatment (color scheme indicated).  The 
bar graph illustrates the group-averaged MMN (±SEM) during the 70-155ms post-
stimulus period and averaged across the above scalp locations. b. GFP waveforms from 
all stimulus conditions and MMN magnitude are displayed following each type of 
treatment. Conventions are identical to those in a. 
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components. These values were submitted to a 2x2 ANOVA using treatment and 
stimulus condition as within subjects factors. Only the main effect of stimulus condition 
was significant (F(1,6)=30.212; p=0.002), whereas the main effect of treatment and the 
interaction between these factors both failed to meet the 0.05 significance criterion (all 
p-values>0.30). This pattern of results would suggest that the P300 was intact in 
patients both when receiving placebo as well as when receiving NAC. This AEP 
component showed no indication that it was modified by NAC treatment, in contrast to 
the earlier MMN response. 
7.3.2.3  Neuropsychological and psychopathological results 
The scores obtained during neuropsychological tests showed no effect of NAC 
treatment when compared to placebo (data not shown). These data were pooled with 
those of the larger clinical trial to be presented elsewhere (Berk et al., 2006). 
7.3.2.4  Biochemical results 
Levels of thiols linked to GSH were measured in blood from patients after NAC and 
after placebo treatment. Results are summarized in Table 2. After NAC treatment, an 
increase in total GSH levels was observed in whole blood (F(1,9)=20.89; p=0.006) as 
well as in blood cells (F(1,9)=29.87; p=0.001). However, this increase relative to placebo 
did not exceed 10%. There was no increase in cysteine and cysteinyl-glycine. No 
correlation was found between the magnitude of these biochemical changes and our 
electrophysiological measures. 
 
Table 6. Levels of GSH and its cysteine-related precursors measured in blood from 
patients after NAC treatment and placebo. Bold p-values indicate significant difference. 
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8. Discussion           
The present work has enabled us to demonstrate that it is possible to increase GSH 
levels using three different strategies: bypassing the limiting enzyme GCL, boosting the 
activity of this enzyme and providing more of the limiting precursor cysteine.  
8.1 Bypassing the limiting enzyme GCL 
8.1.1 Neurons vs astrocytes 
In schizophrenia patients, the deficit in GSH observed is due to a defect at the level of 
the limiting synthesizing enzyme, GCL (Gysin et al., 2005;Tosic et al., 2006). We 
therefore used cultured astrocytes and neurons with a deficit in GSH as models. This 
deficit was induced with BSO, an inhibitor of GCL. To achieve the same percentage of 
decrease, that is about 70%, 10 times less BSO was necessary in astrocytes compared to 
neurons, indicating that GCL in astrocytes can be tuned more rapidly. Results from the 
group of Dalton suggest that, in most tissues, the GCLC/GCLM ratio is > 1, and that 
GCLM is limiting (Chen et al., 2005). It is possible that this ratio is lower in astrocytes 
than in neurons and, since BSO inhibits the catalytic subunit, a stronger inhibition will 
be nessary in neurons than in astrocytes to reach the same ratio. It is know that basal 
GCL activity in astrocytes is higher than in neurons (Gegg et al., 2003;Makar et al., 
1994), which is in agrement with a low GCLC/GCLM ratio in astrocytes, considering 
that GCLM is limiting. Furthermore, astrocytes have been reported to have higher GSH 
levels than neurons (Bolanos et al., 1995;Gegg et al., 2003;Raps et al., 1989;Sagara et 
al., 1993). This difference in their GSH contents may account for their differential 
response to GCL inhibitors, such as BSO (Dukhande et al., 2006). Dukhande and 
collaborators also observed than less BSO is necessary to decrease GSH levels in 
astrcytes-like cells (U87) compared to neuron-like cells (SK-N-SH). In our hands, 
astrocytes presented GSH levels about three times higher than neurons, with basal 
values of 29.1 nmol/mg and 8.5 nmol/mg respectively. 
8.1.2 GSHEE increases GSH levels in cultured astrocytes and neurons 
BSO-treated cells allow us to investigate how an increase in GSH levels can be 
achieved when the limiting synthesizing enzyme is not functional. The only way to 
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reach our goal is by bypassing GCL. Since GSH itself is not transported inside the cell 
(Meister, 1989), membrane permeable esterified analogs of GSH and its precursor γ-
glucys were used. 24-hour incubation with GSHEE significantly increased GSH 
contents in BSO-treated neurons and astrocytes to levels similar to those measured in 
control cells (Figures 11A and 12A). The concentration of GSHEE necessary to reach 
these levels was three times higher in astrocytes than in neurons, which is not surprising 
considering the basal GSH levels that are three times more elevated in astrocytes than in 
neurons. GSHEE also induced an increase in GSH contents in control neurons, but not 
in astrocytes, in which a plateau seems to be reached around the concentration of 
30nmol/mg prot.  
8.1.3 GCEE increases GSH levels in astrocyte, but not in neurons 
GCEE could not increase GSH levels neither in controls, nor in BSO-treated neurons 
(Figure 13A), meaning that providing more γ-glucys is not leading to more GSH in this 
cell type. In view of these results, it seems like GSH analogs are more efficient than γ-
glu-cys analogs in increasing GSH levels in neurons. These results contrast with those 
obtained by Boyd-Kimball and collaborators (2002), showing that GCEE can 
successfully increase GSH levels in BSO-treated neurons. This discrepancy is difficult 
to interpret since the duration of treatments, the concentration of GCEE, as well as the 
medium used, were the same in both their and our study. The only other difference is 
that they used hippocampal neurons from rats, while we used cortical neurons from 
mice. It has already been stated that the differences in the reported glutathione levels 
from a study to another might be attributed to differences in preparation techniques, 
species used, or culture conditions (Dringen, 2000). In astrocytes, GCEE was as much 
efficient as GSHEE, increasing GSH levels in BSO-treated cells to levels similar to 
those observed in controls (Figure 14A). A concentration of 3mM was again necessary, 
lower concentrations only partially, but linearly, increasing GSH levels. Our results 
suggest that the precursor γ-glucys is more readily used in astrocytes than in neurons. 
This is quite surprising, since it was shown that the extracellular concentration of glucys 
and γ-glucys providing half-maximal effects on GSH synthesis are lower in neurons 
than in astrocytes., indicating than neurons are more efficient in utilizing these 
compounds than astrocytes (Dringen, 2000). Furthermore, GSS, the enzyme that uses γ-
glucys as a precursor, is usually not limiting. Howerver, lines of evidence suggest a 
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more prominent role for GSS in GSH regulation than previously recognized. For 
exemple, increased rat GSS and GCLC expression further enhanced GSH synthesis 
above that observed with increased GCLC expression alone (Huang et al., 2000).  
8.1.4 GSH replenishment ameliorates NMDA function 
In any case, GSHEE being more efficient than GCEE in increasing GSH levels in 
neurons, we chose to use this substance in the study of the effects of GSH 
replenishment in BSO-treated neurons on NMDA response. Recently, we observe that 
neurons with a deficit in GSH, show an altered modulation of NMDA responses by 
dopamine (Steullet et al., submitted). In control neurons, dopamine-enhanced NMDA-
mediated calcium response (NMDA responses), while in BSO-treated neurons, 
dopamine decreased this response. Restoring normal GSH levels in BSO-treated 
neurons abolished the alteration of the dopamine modulation of NMDA responses 
(Figure 15). Indeed, the dopamine-induced decrease in NMDA responses in BSO-
treated was no longer observed in BSO-treated neurons incubated with GSHEE. These 
results demonstrate that a depletion of intracellular GSH was responsible for the 
dopamine-induced decrease of NMDA responses observed in BSO-treated neurons and 
that GSH replenishment with GSHEE could re-establish normal dopamine modulation 
of these NMDA responses. Data suggest that enhancement of the function of redox 
sensitive ryanodine receptors (RyRs) in neurons with low GSH levels favors D2-type 
receptor-mediated and calcium-dependent pathways, causing a change in dopamine 
modulation of L-type calcium channels, and ultimately in dopamine modulation of 
NMDA response (Steullet et al., submitted). Rectifying the redox status with GSHEE in 
neurons probably abolishes this indirect effect of RyRs on NMDA response.  
GSHEE being the direct analog of the substance we are interested in, that is GSH, it 
would be the best choice for a therapeutical approach using a substance that do not need 
a funtionnal GCL for increasing GSH levels. I.p.-injection or oral administration of 
GSHEE in mice increases GSH levels in liver and kidney (Anderson et al., 1985). 
Increase in these levels was also observed in spleen, pancreas, and heart, but not in 
brain. However, another study by the same group has shown that GSHEE is well 
transported into the cerebrospinal fluid (Anderson et al., 1989), indicating that GSH 
levels might be increased in only some parts of the brain.  
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More lipophilic derivates of GSH might also be useful. But, the toxicity of such 
derivative needs to be considered. Indeed, propanol, isopropanol and butanol are much 
more toxic than ethanol, the hydrolysis product of GSHEE (Anderson et al., 1985). 
GSH diethyl ester might be transported more rapidly than GSHEE (Levy et al., 1993). 
However, its deesterification is slower and the release of two ethanol instead one might 
represent a higher risk of toxicity. Morphological alterations with the ethyl esters of 
GSH has been noted previously (Scaduto, Jr. et al., 1988;Tsan et al., 1989), indicating 
that caution should be taken for its use in vivo. Considering the fact that GSH levels in 
the brain are in the range of the millimolar levels (Cooper and Kristal, 1997), a very 
high concentration of GSHEE could be necessary to reach these levels and toxicity 
could become an issue. In interesting alternative, the GSH-glycoside should be taken 
into consideration. Indeed, the effectiveness of GSH-glycoside in increasing GSH levels 
was demonstrated in vitro and in vivo (Choi et al., 1996). This substance is readily 
transported inside the cells and the glycoside release is unlikely to show toxicity.  
8.2 Boosting the limiting enzyme GCL 
BSO model was useful in the study of substances that bypass GCL. However, even if 
this enzyme is impaired in schizophrenia, its activity is unlikely to be completely 
blocked in patients. Therefore, boosting this enzyme in such a way that it produces 
more GSH is the second strategy that was used in the present thesis work. Based on 
literature, search for substances susceptible to increase GSH levels and GSH-related 
gene expression has led us to focus on curcumin, quercetin and tBHQ. Curcumin, a 
polyphenol, and quercetin, a flavonoid, are two naturally occurring compounds. TBHQ, 
a synthetic antioxidant, is a well-known activator of Nrf2 pathway. These three 
substances were shown to increase GSH levels in various cell types, most likely via an 
induction of phase II genes. In the present study, we were interested in increasing GSH 
levels in brain cells, and in studying the mechanisms by which this increase is achieved. 
We observed that curcumin and tBHQ could increase GSH levels in cultured neurons 
and astrocytes, while quercetin succeeded only in astrocytes.  
8.2.1 Induction of phase II genes 
All three substances were shown to induce phase II detoxifying and antioxidant-related 
genes (Lee et al., 2003;Myhrstad et al., 2002;Scapagnini et al., 2006;Vargas et al., 
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2006). Curcumin, quercetin and tBHQ, although they have different chemical 
structures, all contain electrophilic unsaturated carbonyl groups. These groups can react 
selectively with nucleophiles such as thiols that are present on Keap1 (figure 5). The 
change in the conformation of keap-1 that is induced following the oxidation of the thiol 
group, leads to the dissociation of the cytoplasmic Nrf2-Keap1 complex, allowing Nrf2 
to translocate into the nucleus (Jaiswal, 2004). The transcription factor Nrf2 was shown 
to be essential for the coordinate induction of phase II detoxifying and antioxidant 
enzymes, both of which are under ARE regulation (Ishii et al., 2000;Itoh et al., 1999). 
Nrf2 binds to the ARE and transcriptionally activates downstream target genes (Zhang 
and Gordon, 2004). Among these genes that contain an ARE sequence in their 
promoter, we find many GSH-related genes: Nrf2 itself (Kwak et al., 2002), 
glutathione-S-transferases (GST)(Rushmore and Pickett, 1990), the catalytic (Mulcahy 
et al., 1997) and the modulatory (Moinova and Mulcahy, 1998) subunits of GCL, as 
well as the specific subunit of the cysitine-glutamate exchanger, xCT (Sasaki et al., 
2002). An ARE sequence was also described upstream of the promoter region of the 
gene of 4F2, the ubiquitous subunit of the exchanger (Sato et al., 2004), but its 
expression was not increased by diethyl maleate, an ARE inducer and thiol conjugate 
(Sasaki et al., 2002). Concerning GPx, the situation is not so obvious. Five GPxs were 
identified in mammals, all showing distinct roles in the cellular defense mechanisms. 
Gastrointestinal GPx gene was shown to be a target for Nrf2 (Brigelius-Flohe, 2006), 
but to date, no data are available about the action of Nrf2 towards brain GPx. Finally, 
GSS promoter region was recently characterized and two Nrf2 binding sites, highly 
homologous to ARE sequence, were identified (Lee et al., 2005).  
Following treatment with curcumin, quercetin and tBHQ, we measured mRNA levels of 
Nrf2, of the two subunits of the cystine-glutamate exchanger (xCT and 4F2), the two 
subunits of the rate-limiting GSH synthesizing enzyme GCL [the modulatory (GCLM) 
and the catalytic (GCLC)], the second GSH synthesizing enzyme GSS and finally, GPx, 
one of the two enzymes implicated in the redox cycle. The second one, GST, being 
present in many isoforms, we did not measure their mRNA levels, but rather the activity 
of the enzymes using CDNB as a conjugate. This compound was shown to be the most 
ubiquitous in regard to the various isoforms of GST (Habig et al., 1974). Of course, 
being interested more specifically on boosting GCL, we measured the activity of this 
enzyme. Finally, in order to have an idea of the toxicity of the substances used towards 
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the cells, the activity of LDH leaking in the culture medium out of dying cells was 
measured. 
8.2.2 Curcumin increases GSH levels in both astrocytes and neurons 
Curcumin, a naturally occurring polyphenol, could increase GSH levels in neurons, and 
even more in astrocytes (Figures 21 and 22). Curcumin was shown to increase GSH in 
different cell lines, such as cultured human erythroleukemia (Singhal et al., 1999), type 
1 astrocytes from rat (Scapagnini et al., 2002), human bronchial epithelial (Dickinson et 
al., 2003), human myelomonocytes (Strasser et al., 2005) and human alveolar epithelial 
(Biswas et al., 2005). This increase in GSH levels could be due to an increase of de 
novo GSH synthesis following the increased activity of GCL due to an induction of its 
expression by Nrf2. Indeed, curcumin was shown to increase Nrf2 protein levels in 
nuclear extracts from rat astrocytes, already one hour after the beginning of the 
treatment. Nrf2 translocation to the nucleus was accompanied by an upregulation of 
some phase II enzymes in these cells (Scapagnini et al., 2006).  
Low concentration of curcumin (10µM) caused an increase in gene expression of Nrf2, 
xCT, 4F2 and GCLM in neurons, but only a small increase expression of GCLM and 
GSS in astrocytes. Thus, low curcumin concentration was able to boost more efficiently 
the whole system of GSH synthesis in neurons than in astrocytes. This certainly 
explains why such concentration of curcumin  was more efficient in increasing GSH 
levels in neurons than in astrocytes. In neurons, the transport system for cystine was 
upregulated. This suggests that, although neurons in general seem to have a preference 
for the transport of cysteine (Shanker et al., 2001)  via the excitatory amino acid 
transporter EAAT (Chen and Swanson, 2003), these cell can transport cystine when 
oxidative stress occurs. Even if only GCLM mRNA levels were increased, and not 
GCLC, the activity of the enzyme was increased by 50%, suggesting that upregulating 
the modulatory subunit is sufficient to boost GCL in neurons. Considering that GCLM 
is the limiting subunit (Chen et al., 2005), increasing its levels will lead to an increase in 
the GCLC/GCLM ratio, and therefore an increase in the catalytic activity of the 
enzyme. 
In astrocytes, a higher concentration of curcumin (50µM), which led to a very high 
increased in GSH levels, strongly boosted the entire system of GSH synthesis, from the 
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cysteine uptake to the synthesis itself, apart from GPx. As mentioned earlier, brain 
GPx’s promoter region has not been characterized yet (Brigelius-Flohe, 2006), and it is 
possible that it does not contain the ARE sequence. Furthermore, knowing that GPx is 
necessary for the reduction of ROS, free radicals might be better inducers than 
electrophiles. The gene expression of the two subunits of the cystine transporter, the 
system xc-, was upregulated, allowing more cysteine, the limiting precursor in the 
synthesis of GSH, to be available inside the cells. mRNA levels of the two GSH 
synthesizing enzymes were increased, with a really high level for the GCLM subunit. 
The increase in the gene expression of the two subunits of GCL was accompanied by an 
increase of 150% in the activity of the enzyme. However, with 100µM, while GCL 
activity is still high, the increase in GSH levels is less significant that with 50µM. This 
suggests that some of the GSH produced is immediately used.  
The difference between the two cells types is not so surprising given that the expression 
of phase II detoxification enzymes is generally lower in neurons (Eftekharpour et al., 
2000;Kraft et al., 2004;Murphy et al., 2001). Neurons can respond to lower 
concentrations, but they are unable to respond as strongly as astrocytes during a strong 
challenge.  
Our results are consistant with those obtained using human lung epithelial cell lines. An 
increase in the content of GCLC (Biswas et al., 2005) and GCLM mRNA, as well as in 
the content of both GCL subunit proteins were observed after a treatment with curcumin 
(Dickinson et al., 2003). Furthermore, curcumin was shown to induce 1.6 fold increase 
in GCL activity in human erythroleukemia cells line (Singhal et al., 1999). The decrease 
in GST activity that we observed in astrocytes are consistent with other studies showing 
that curcumin is a substrate inhibitor of human (Awasthi et al., 2000;Hayeshi et al., 
2007) and rat (Oetari et al., 1996) GSTs. However, these results show a discrepancy 
with studies that demonstrated that curcumin could significantly increase the expression 
of GST, a member of the phase II detoxification enzymes in cultured astrocytes 
(Scapagnini et al., 2006). Furthermore, unsaturated carbonyl compounds are substrates 
for GSTs (van Iersel et al., 1997), therefore participating to their own elimination from 
the cell. In vivo studies will be required to assess the overall effect of curcumin 
compounds on GSTs. On the other hand, the observed increase in GSH indicates that 
formation of the conjugate of curcumin with GSH is not a significant route for 
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metabolism of curcumin, since this reaction would tend to decrease GSH levels. These 
results are consistent with previous metabolic studies in rat liver which indicated that 
curcumin is metabolized primarily to glucuronides and sulfates (Holder et al., 1978).  
Our results show that curcumin is efficent in increasing GSH levels in both astrocytes 
and neurons. This substance could therefore be considered as a therapeutical approach 
for protecting cell against oxidative stress in the case of a deficit in GSH. Of course, 
apart from its ability to increase GSH levels, curcumin shows its own protective effect.  
Structurally, curcumin does not have the typical ring structure of polyphenol 
compounds, possessing a diketone group and two phenol rings that act as electron traps 
to prevent H2O2 production and to scavenge OH• and superoxide radicals. Besides, both 
the hydroxyl groups and the diketone moiety of curcumin are involved in metal-ligand 
complexation (Daniel et al., 2004). Curcumin can chelate Fe2- needed for the generation 
of OH radicals (Reddy and Lokesh, 1994). However, at high concentration, this 
substance leads to a decrease in GSH levels accompanied by significant cell death in 
astrocytes. In neurons, neither GSH levels nor cell viability are decreased, but the trend 
in an increase in GSSG levels relative to GSH leads one to presume that higher 
concentrations could be noxious. Therefore, the choice of the concentration to be used 
in an in vivo would be primordial, considering that a concentration high enough to reach 
the brain will be necessary, but without inducing toxicity.  
8.2.3 Quercetin increase GSH levels in astrocytes, but not in neurons  
Quercetin, a naturally occurring flavonoid, could increase GSH levels in astrocytes, but 
not in neurons (Figures 24 and 25). This substance was shown to increase GSH levels in 
human breast cancer cells (Rodgers and Grant, 1998), monkey kidney derived cells 
(Myhrstad et al., 2002) and human hepatoma cell line (Alia et al., 2005;Scharf et al., 
2003). In an in vivo study, quercetin could enhance the exploratory behavior, spatial 
learning and memory of the mice, these effects being related with an increase in brain 
GSH level (Liu et al., 2006). However, apart from its neuroprotective effects (Zhu et al., 
2007), its effects in brain cells regarding GSH levels have never been investigated in 
cultures. This substance was shown to induce the ARE-dependent genes, in human 
breast carcinoma cell line (Valerio et al., 2001), and in monkey kidney cell line 
(Myhrstad et al., 2002).  
 86
In our study, quercetin induced roughly the same sets of GSH-related genes than 
curcumin in astrocytes. 20µM quercetin increased mRNA levels of xCT, GCLM and 
GSS in astrocytes already after 8h and, after 18h, the increase in GCLC gene expression 
reached significance. Quercetin seems to be less efficient that curcumin in inducing 
ARE-related genes and increasing GSH levels. This is consistant with a study that 
showed that curcumin, but not quercetin, is neuroprotective in a rat model of 
Parkinson’s disease (Zbarsky et al., 2005). This result may also have been determined 
by variable metabolism by the intestinal flora and systemic availability and ability to 
cross the blood brain barrier (Manach and Donovan, 2004). For the cystine-glutamate 
exchanger, only the subunit xCT, but not 4F2, was induced by quercetin in astrocytes. 
xCT being specific for the cystine-glutamate exchanger, and 4F2 being ubiquitous to 
many transporters, it is possible that the expression of xCT is preferentially increased 
when the need for a boost in the cellular defense mechanisms occurs. As for curcumin, 
quercetin did not lead to an increase in mRNA levels of GPx and the two GSH 
synthesizing enzymes were upregulated, with a really high level for the GCLM subunit. 
The increase in the gene expression of the two subunits of GCL was accompanied by an 
increase of 100% in the activity of the enzyme. However, this increase led to only 50% 
more GSH. This result suggests that some of the de novo GSH synthesized is 
immediately used, either for the elimination of quercetin itself or for the scavenging of 
free radical potentially induced by the presence of quercetin in the cell. The last 
hypothesis does not seem realistic considering that the percentage of GSSG relative to 
GSH is unchanged. The polyphenolic structure of quercetin allows scavenging of free 
radicals, and when quercetin reacts with ROS, potentially harmful ortho-quinone (Boots 
et al., 2003). This product is then inactivated by GSH, to form two non reactive 
products: 6- glutathionyl-quercetin (6-GSQ) and 8-glutathionyl-quercetin (8-GSQ). In 
our study, no increase in the activity of GST was observed. Quercetin has been 
previously shown to inhibit GST (Kurata et al., 1992;van Zanden et al., 2003;Zhang and 
Das, 1994), but the nature of this inhibition has not been elucidated yet.  
While no increase in cell death was observed in astrocytes, not only GSH levels were 
decreased in neurons, but quercetin, at high concentrations, led to an increase in cell 
death. Cell death after treatment with quercetin has been observed (Alia et al., 2005), 
and quercetin caused depletion of reduced glutathione which occurred prior to cell death 
(Duthie et al., 1997), probably because of the conjugation of the ortho-quinone with 
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GSH (Boots et al., 2003). Thus, it was proposed that quercetin can exert an antioxidant 
effect in the presence of high levels of GSH (Ferraresi et al., 2005), otherwise, it 
becomes pro-oxidants. Therefore, long exposure to quercetin results in a consumption 
of GSH and, in this case, reactive radical intermediates of quercetin cannot be 
scavenged anymore. As a consequence, the pro-oxidant effect of this molecule could 
prevail over the antioxidant effect. We cannot exclude that quercetin could boost GSH 
synthesis in neurons, but this could not compensate for the use of GSH for the 
elimination of quercetin itself. The pro-oxidant activity of quercetin may deplete the 
nuclear antioxidant defense, increasing nuclear lipid peroxidation and leading to 
oxidative DNA damage (Sahu and Gray, 1996). These results contrast with those 
showing that quercetin can protect membranes against lipid peroxidation (Decharneux 
et al., 1992;Laughton et al., 1991). 
These contradictory results, but even more the fact that quercetin shows potential 
noxious effect, speak against the use of this substance in a therapy for increasing GSH 
levels. 
8.2.4 tBHQ increases GSH levels in both astrocytes and neurons 
tBHQ, a synthetic phenolic antioxidant, could increase GSH levels in both astrocytes, 
and neurons (Figures 27 and 28). tBHQ is a well studied inducer of phase II genes. This 
substance could strongly increase mRNA levels of all the GSH-related genes that we 
studied, except GPx in neurons and Nrf2 in astrocytes. The fact that the expression of 
Nrf2 was not increase in astrocyte is surprising considering the huge increase in mRNA 
levels of xCT and GCLM, already observed after 8h. In a study where tBHQ was used 
to induce ARE-driven genes in astrocytes, this substance did not increase Nrf2 
expression levels, but induced nuclear translocation of Nrf2 (Lee et al., 2003). These 
results suggest that ARE activation by tBHQ is mediated by nuclear translocation of 
Nrf2, not by induction of Nrf2 gene expression in primary astrocytes. Furthermore, 
electrophilic compounds can induce these genes via the Keap1-Nrf2 pathway, but it 
seems like other pathways, one implying MAP kinase and another implying IP3 kinase, 
could also lead to the induction of ARE-driven genes (Nguyen et al., 2003). tBHQ is 
believed to be an activator of these cascades. This could explain why tBHQ activates 
ARE-regulated genes more strongly than curcumin and quercetin.  
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In our study, Nrf2 was induced in neurons, showing again the difference between the 
two cell types in the strategies they use to induce the antioxidant defense. Indeed, while 
neurons need to increase Nrf2 gene expression, astrocytes already containing enough of 
the protein can initiate the Nrf2/ARE cascade more rapidly. This could explain why the 
expression of some genes was already increased in astrocytes but not in neurons after 
only 8h. tBHQ could induced the expression of GSS in neurons, which was not the case 
for curcumin. tBHQ had stronger effects than curcumin on gene expression, but did not 
lead to larger GSL activity and GSH levels in neurons. This might be due to the limited 
increase in the gene expression of the catalytic subunit of GCL. This situation was also 
observed in astrocytes. Indeed, the 42 times increase in GCLM gene expression with 
100µM tBHQ in astrocytes was accompanied by only 6.5 times increase in mRNA 
levels of GCLC. The activity of GCL was increased as much as after a treatment with 
curcumin, but not more. This suggests that even if GCLM is over expressed and 
positively modulates the activity of GCLC, if the catalytic subunit is not present in 
sufficient amount, the activity of the enzyme reaches a plateau. In this case the 
GCLC/GCLM ratio becomes inferior to 1. Like for quercetin treatment, the tBHQ-
induced increase in GCL activity was higher than the increase in GSH levels. This 
suggests that some of the the novo GSH synthezised was immediately used, either for 
the elimination of tBHQ itself or for the scavenging of free radical potentially induced 
by the presence of tBHQ in the cell. Indeed, tBHQ, following a dealkylation step, can 
undergo oxidation-reduction reactions within cells and, in this case, is acting as a pro-
oxidant (Nguyen et al., 2003). The oxidation of tBHQ to its corresponding quinone, 
tert-butylquinone, is accompanied by the generation of ROS (Kahl et al., 
1989;Schilderman et al., 1993). These ROS must be detoxified and, indeed, the increase 
in the expression of GPx is accompanied by a trend in an increase in the percentage of 
GSSG relative to GSH with 100µM tBHQ. At this concentration, GSH levels are no 
longer significantly increased and a trend in cell death can be observed, meaning that 
the cell cannot cope anymore with the toxic effects of tBHQ. The same was observed in 
neurons, where 10µM and 20µM tBHQ could increase GSH levels, while higher 
concentrations led to cell death. 
Despite tBHQ is a strong inducer of detoxifying and antioxydant enzymes, it potential 
toxic effect should be considered with caution, like it is the case of curcumin and 
quercetin at high concentrations. 
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8.2.5 Astrocytes are neuroprotectors 
Our results, consistently with others, show that ARE-driven genes are prefentially 
activated in astrocytes compared to neurons (Eftekharpour et al., 2000;Kraft et al., 
2004;Murphy et al., 2001), although at low concentrations of curcumin and tBHQ, 
neurons seems to be as efficiently, if not more, than astrocytes. Following stonger 
activation, astrocytes have more efficient GSH synthesis systems as well as higher GSH 
content than neurons, and export GSH to the extracellular media (Dringen et al., 2000). 
Secreted GSH can protect neurons acting as an antioxidant in the extracellular 
compartment and boosting GSH levels in neurons by increasing the availability of 
cysteine (Dringen et al., 1999). 
8.2.6 The modulatory subunit is necessary for the action of the substances 
Curcumin, quercetin and t-BHQ significantly increased the expression of the cystine-
glutamate exchanger, the two subunits of GCL (GCLM and GCLC) and GSS in 
astrocytes of normal mice. This was accompanied by an increase in GCL activity and 
GSH levels. Because of the observed decrease in GCLM mRNA in fibroblasts of 
patients and the genetic association between the GCLM gene and schizophrenia, we 
assessed the importance of this subunit in the induction of GCL and the subsequent 
increase in GSH levels, using astrocytes from GCLM KO mice. The three substances 
could significantly increase GCLC gene expression in astrocytes from normal mice 
(OF1). Due to material limitation, mRNA levels could not be measured in cells from 
GCLM KO mice. We suppose that GCLC gene regulation is the same in astrocytes from 
OF1 and from GCLM KO. The inhability of the substances to increase GCL activity 
and GSH levels in astrocytes lacking a functional GCLM demonstrates that GCLM was 
necessary to increase GSH levels. An upregulation of cystine transport, GCLC subunit 
and GSS was not sufficient in absence of GCLM. However, even if a defect in GCLM 
is related to schizophrenia, patients are not knocked-out for this gene, so upregulating 
its expression could theoretically still be achieved.  
8.2.7 FK506 has no effect in both astrocytes and neurons 
Finally, we also tested the efficacy of an immunosuppressant, FK 506, in increasing 
GSH levels in cultured neurons and astrocytes. Indeed, the group of Tanaka et al. (2000, 
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2001, 2002 and 2004), showed that GSH levels were increase by FK506 in 
neuroblastoma cell line, neuroblastoma-glioma hybrid cell line and glioma cell lines. 
However, the mechanisms by which this immunosuppressant can increase GSH levels 
are unclear. The same group has conducted an in vivo study during which FK506 was 
i.p.-injected to mice and they observed an increase in GSH levels in striatum, as well as 
an increase in gene expression of GCL. However, no distinction was done between the 
whole GCL and its subunits, regarding the mRNA quantification, which it quite 
intriguing. No change in mRNA levels of GPx or GST were observed, leading one to 
doubt about the phase II enzyme-induction activity of FK506. In our hand, FK506 had 
no effect on GSH levels in both neurons and astrocytes, neither did the cell viability was 
affected. Therefore, no further investigations were done. 
8.3 Providing more of the limiting precursor cysteine 
NAC, a precursor of GSH, given as an add-on treatment (2 g / day for 2 months) to 
schizophrenia patients, induces an increase in auditory evoked MMN, likely reflecting 
an improvement in NMDA-R function. 
8.3.1 MMN is impaired in schizophrenia patients 
It had already been shown that MMN is impaired in schizophrenia patients (Catts et al., 
1995;Javitt et al., 1993;Javitt et al., 1998;Shelley et al., 1991;Shutara et al., 1996) and 
this was the case again in our small group of patients at protocol onset, compared to sex 
and age-matched controls (figure 38). In fact, during the auditory oddball paradigm 
(AOP), the difference observed in controls between the GFP induced by the target and 
by the distractor around 100 ms was not present in patients at the beginnig of the 
clinical trial. GFP is equivalent to the spatial standard deviation of the scalp electric 
field, and quantifies the amount of activity at each time point in the field, considering 
the data from all recording electrodes simultaneously. It is therefore a measure of the 
global strength of the scalp electric field at each time-point and these values are plotted 
as a function of time. Changes in the amplitude of the GFP indicate a change in the 
strength of the underlying generator, while a change in the map topography indicates a 
change in the generators themselves. The map topography induced by the target was the 
same for control and patients between 70 and 155 ms (figure 39). However, the 
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amplitude of the GFP was different, indicating that the capacity to evoke MMN is 
reduced in schizophrenia patients.  
8.3.2 NAC improves MMN generation 
A group of patients was treated with NAC for two months and then with placebo for 
another two-month period, and vice-versa for a second group. Our results show that 
patients treated with 2g of NAC per day show improved MMN. Analyses of AEPs 
recorded after NAC treatment versus placebo revealed the efficacy of this GSH 
precursor in modulating MMN generation mechanisms. In fact, we observed an increase 
in the amplitude of the GFP of MMN after NAC treatment that was not present after 
placebo (figure 40), indicating that NAC ameliorates MMN generation. 
8.3.4 NAC increases blood GSH levels 
An increase of GSH levels in blood was measured in our subset of patients after NAC 
treatment (table 6), showing that NAC was absorbed, at least in part, by the gastro-
intestinal system. No increase in cysteine levels was observed in blood from patients 
after NAC treatment. This could suggest that all the deacetylated cysteine is 
immediately used and that higher doses of NAC could be considered for treatment. On 
the other hand, even though single oral doses of NAC leads to an increase in NAC 
levels in plasma, it does not appear to accumulate (Borgstrom and Kagedal, 1990). In 
this case, a more frequent intake of NAC would ensure more sustained concentrations. 
The present study was conducted in the context of a multicenter clinical trial. The 
effectiveness of NAC in reducing clinical severity was demonstrated over the whole set 
of 140 patients included in the multicenter trial and randomly assigned to either NAC or 
placebo treatment (Berk et al., 2006). An improvement on the Clinical Global 
Impression (CGI) was observed already two weeks after the beginning of the trial and 
was sustained for the 6-months trial period. An improvement of symptoms on the 
Positive and Negative Symptoms Scale (PANSS) was also significant after 6 months of 
treatment with NAC. 
We hypothesise that a fraction of the oral NAC entered blood flow, crossed the blood-
brain barrier (Farr et al., 2003), was deacetylated into cysteine that could readily be used 
to increase GSH levels. As already mentioned, GSH being the major antioxidant in a 
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cell system, its presence is necessary to maintain equilibrium on the redox status. In 
fact, redox-sensitive proteins such as NMDA-R, which are implicated in the generation 
of MMN (Javitt et al., 1996), can have their activity decreased when the ratio 
GSH/GSSG becomes too low (Janaky et al., 1993;Sucher and Lipton, 1991). Indeed, 
GSH deficit in hippocampus slices leads to NMDA-R hypofunction and inhibition of 
long-term potentiation (Steullet et al., 2006). Therefore, it is plausible that the absence 
of MMN in patients could be due, at least in part, to hypofunction of NMDA-R 
subsequent to a GSH deficit. In patients with low brain GSH, NAC could increase GSH 
levels, and thus improving the functioning of NMDA-R. Therefore, the increase of 
MMN observed after NAC treatment is likely to correlate with a better functioning of 
NMDA-R. 
However, from our data, we cannot conclude with certitude that the effect of NAC is via 
its cysteine donor property. In fact, NAC being an antioxidant itself, it is possible that it 
has a direct effect on the redox properties of NMDA-R. NAC can also affect gene 
regulation of detoxifying enzymes by activating redox-sensitive transcription factors, 
such as nuclear factor κB (NF-κB) and activator protein 1 (AP-1; Cotgreave, 1997). To 
assess if NAC really elevates GSH levels in the brain of schizophrenia patients, in vivo 
magnetic resonance spectroscopy (MRS) would be necessary. However, it has been 
reported that with current MRS methods, the signal to noise ratio would need to be 
improved in order to observe discrete increases in brain GSH levels (Trabesinger et al., 
1999). 
9. Conclusion           
GSHEE, a substance that can penetrate the cells, be de-esterified and directly be used as 
GSH in the cell, is highly efficient in increasing GSH levels and showed no toxicity in 
our models. Using this subtance in neurons previously deprived in GSH with BSO, 
could restore normal NMDA functions, that was impaired in the presence of dopamine. 
This substance is therefore of high interest in a therapy aiming at increasing GSH levels, 
since its action is direct and, at first glance, safe. However, considering the high 
concentrations that would be necessary for the substance to reach the brain and 
efficiently increase GSH levels inside brain cells, finding the appropriate delivery mode 
remains a challenge. 
 93
Substances that can induce ARE-driven genes, including the two subunit of GCL, the 
limiting enzyme in the synthesis of GSH, are tempting therapeutic agents. Indeed, 
curcumin and tBHQ could increase GSH levels in both neurons and astrocytes, and 
quercetin was efficient in astrocytes. Their potential toxicity leads one to be cautious 
before considering it as a clinical treatment. However, considering the low 
bioavailability of these substances, it would be surprising that toxic levels would be 
reached in the brain.  
MMN, a component of the AEP that is typically impaired in schizophrenia, was 
improved following a treatment with NAC, a precursor of GSH, supporting the 
hypothesis of a deficit in GSH in the brain of schizophrenia patients. However, 
considering that brain GSH deficiency in schizophrenia seems to be due to a defect in 
the key synthesizing enzyme GCL (Tosic et al., 2006), a cysteine precursor might not 
represent the best substance to use in order to increase GSH levels. Substances that 
bypass the enzyme GCL or that boost this enzyme, as discussed in the two previous 
sections would represent better choices, however raising new challenges for their 
efficient delivery into the brain.  
In conclusion, modulating GSH levels in the brain of patients might already be 
considered as a promising pathway towards an effective long-term therapeutic strategy 
in schizophrenia. Indeed, in view of the side effects induced by current neuroleptics, 
clinicians should consider the administration of naturally occurring antioxidants, or safe 
GSH analogs or precursors. These substances are interesting for high-risk patients 
during prodromic phase or first episode patients with a diagnosis not well established. 
 
 94
10. Abbreviations          
ARE   antioxidant response element  
BSO  L-buthionine-(S,R)-sulfoximine 
GCEE   γ-glutamylcysteine ethyl ester  
GCL  glutamylcysteine ligase 
GCLM glutamylcysteine ligase modulatory subunit 
GCLC  glutamylcysteine ligase catalytic subunit  
GFP  global field power 
γ-glucys γ-glutamylcysteine 
GPx  glutathione peroxidase  
GSH  glutathione 
GSHEE glutathione ethyl ester 
GSR  glutathione reductase 
GSS   glutathion synthetase  
GST   GSH-S-transferase  
γGT   γ-glutamyl transpeptidase  
HZ  heterozygote 
KO  knock-out 
MMN  mismatch negativity  
NAC   N-acetyl-cysteine 
ROS  reactive oxygen species 
WT  wild-type 
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